

Aditya Gupta

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6541867/publications.pdf>

Version: 2024-02-01

627
papers

26,361
citations

4641

85
h-index

14702

127
g-index

639
all docs

639
docs citations

639
times ranked

10733
citing authors

#	ARTICLE	IF	CITATIONS
1	Depression and suicidal ideation in dermatology patients with acne, alopecia areata, atopic dermatitis and psoriasis. <i>British Journal of Dermatology</i> , 1998, 139, 846-850.	1.4	768
2	A large-scale North American study of fungal isolates from nails: The frequency of onychomycosis, fungal distribution, and antifungal susceptibility patterns. <i>Journal of the American Academy of Dermatology</i> , 2000, 43, 641-648.	0.6	453
3	Skin diseases associated with <i>Malassezia</i> species. <i>Journal of the American Academy of Dermatology</i> , 2004, 51, 785-798.	0.6	429
4	The treatment of melasma: A review of clinical trials. <i>Journal of the American Academy of Dermatology</i> , 2006, 55, 1048-1065.	0.6	367
5	Prevalence and epidemiology of onychomycosis in patients visiting physicians' offices: A multicenter Canadian survey of 15,000 patients. <i>Journal of the American Academy of Dermatology</i> , 2000, 43, 244-248.	0.6	329
6	Psychiatric and Psychological Co-Morbidity in Patients with Dermatologic Disorders. <i>American Journal of Clinical Dermatology</i> , 2003, 4, 833-842.	3.3	284
7	Prevalence and epidemiology of toenail onychomycosis in diabetic subjects: a multicentre survey. <i>British Journal of Dermatology</i> , 1998, 139, 665-671.	1.4	267
8	Depression modulates pruritus perception: a study of pruritus in psoriasis, atopic dermatitis, and chronic idiopathic urticaria. <i>Psychosomatic Medicine</i> , 1994, 56, 36-40.	1.3	262
9	Psychodermatology: An update. <i>Journal of the American Academy of Dermatology</i> , 1996, 34, 1030-1046.	0.6	258
10	Antifungal agents: An overview. Part II. <i>Journal of the American Academy of Dermatology</i> , 1994, 30, 911-933.	0.6	252
11	Update in Antifungal Therapy of Dermatophytosis. <i>Mycopathologia</i> , 2008, 166, 353-367.	1.3	245
12	Intermittent dosing of fluticasone propionate cream for reducing the risk of relapse in atopic dermatitis patients. <i>British Journal of Dermatology</i> , 2002, 147, 528-537.	1.4	239
13	Evidence- and consensus-based (S3) Guidelines for the Treatment of Actinic Keratosis " International League of Dermatological Societies in cooperation with the European Dermatology Forum " Short version. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 2069-2079.	1.3	234
14	SUICIDAL IDEATION IN PSORIASIS. <i>International Journal of Dermatology</i> , 1993, 32, 188-190.	0.5	233
15	Seborrheic dermatitis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2004, 18, 13-26.	1.3	215
16	Systematic review of nondermatophyte mold onychomycosis: Diagnosis, clinical types, epidemiology, and treatment. <i>Journal of the American Academy of Dermatology</i> , 2012, 66, 494-502.	0.6	212
17	Ciclopirox nail lacquer topical solution 8% in the treatment of toenail onychomycosis. <i>Journal of the American Academy of Dermatology</i> , 2000, 43, S70-S80.	0.6	198
18	Quantitative culture of <i>Malassezia</i> species from different body sites of individuals with or without dermatoses. <i>Medical Mycology</i> , 2001, 39, 243-251.	0.3	188

#	ARTICLE	IF	CITATIONS
19	Pimecrolimus: A review. Journal of the European Academy of Dermatology and Venereology, 2003, 17, 493-503.	1.3	187
20	Oral cyclosporine for the treatment of alopecia areata. Journal of the American Academy of Dermatology, 1990, 22, 242-250.	0.6	186
21	Prevalence and epidemiology of unsuspected onychomycosis in patients visiting dermatologists' offices in Ontario, Canada - a multicenter survey of 2001 patients. International Journal of Dermatology, 1997, 36, 783-787.	0.5	184
22	Antifungal agents: An overview. Part I. Journal of the American Academy of Dermatology, 1994, 30, 677-698.	0.6	181
23	Onychomycosis in children: Prevalence and treatment strategies. Journal of the American Academy of Dermatology, 1997, 36, 395-402.	0.6	178
24	Safety and efficacy of nonsteroid pimecrolimus cream 1% in the treatment of atopic dermatitis in infants. Journal of Pediatrics, 2003, 142, 155-162.	0.9	177
25	Onychomycosis in the 21st Century: An Update on Diagnosis, Epidemiology, and Treatment. Journal of Cutaneous Medicine and Surgery, 2017, 21, 525-539.	0.6	168
26	Dual mechanism of action of ingenol mebutate gel for topical treatment of actinic keratoses: Rapid lesion necrosis followed by lesion-specific immune response. Journal of the American Academy of Dermatology, 2012, 66, 486-493.	0.6	161
27	Tinea capitis. Medical Mycology, 2000, 38, 255-287.	0.3	152
28	Psoriasis and sex: a study of moderately to severely affected patients. International Journal of Dermatology, 1997, 36, 259-262.	0.5	148
29	Onychomycosis: a review. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 1972-1990.	1.3	148
30	Oral cyclosporine in the treatment of inflammatory and noninflammatory dermatoses. A clinical and immunopathologic analysis. Archives of Dermatology, 1990, 126, 339-350.	1.7	146
31	Cumulative meta-analysis of systemic antifungal agents for the treatment of onychomycosis. British Journal of Dermatology, 2004, 150, 537-544.	1.4	144
32	Epidemiology and prevalence of onychomycosis in HIV-positive individuals. International Journal of Dermatology, 2000, 39, 746-753.	0.5	143
33	The use of antidepressant drugs in dermatology. Journal of the European Academy of Dermatology and Venereology, 2001, 15, 512-518.	1.3	138
34	In vitro susceptibility testing of ciclopirox, terbinafine, ketoconazole and itraconazole against dermatophytes and nondermatophytes, and in vitro evaluation of combination antifungal activity. British Journal of Dermatology, 2003, 149, 296-305.	1.4	138
35	A psychocutaneous profile of psoriasis patients who are stress reactors. General Hospital Psychiatry, 1989, 11, 166-173.	1.2	134
36	Therapeutic Options for the Treatment of Tinea Capitis Caused by Trichophyton Species: Griseofulvin Versus the New Oral Antifungal Agents, Terbinafine, Itraconazole, and Fluconazole. Pediatric Dermatology, 2001, 18, 433-438.	0.5	133

#	ARTICLE	IF	CITATIONS
37	Alcohol intake and treatment responsiveness of psoriasis: A prospective study. <i>Journal of the American Academy of Dermatology</i> , 1993, 28, 730-732.	0.6	131
38	Azathioprine hypersensitivity-like reactions-a case report and a review of the literature. <i>Clinical and Experimental Dermatology</i> , 1995, 20, 353-356.	0.6	131
39	Pruritus in psoriasis. A prospective study of some psychiatric and dermatologic correlates. <i>Archives of Dermatology</i> , 1988, 124, 1052-1057.	1.7	127
40	In vitro susceptibility of the seven <i>Malassezia</i> species to ketoconazole, voriconazole, itraconazole and terbinafine. <i>British Journal of Dermatology</i> , 2000, 142, 758-765.	1.4	126
41	Cutaneous adverse effects associated with terbinafine therapy: 10 case reports and a review of the literature. <i>British Journal of Dermatology</i> , 1998, 138, 529-532.	1.4	122
42	AGE AND GENDER DIFFERENCES IN THE IMPACT OF PSORIASIS ON QUALITY OF LIFE. <i>International Journal of Dermatology</i> , 1995, 34, 700-703.	0.5	121
43	Pityriasis versicolor. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2002, 16, 19-33.	1.3	121
44	Identification and Typing of <i>Malassezia</i> Species by Amplified Fragment Length Polymorphism and Sequence Analyses of the Internal Transcribed Spacer and Large-Subunit Regions of Ribosomal DNA. <i>Journal of Clinical Microbiology</i> , 2004, 42, 4253-4260.	1.8	121
45	The epidemiology of onychomycosis: possible role of smoking and peripheral arterial disease. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2000, 14, 466-469.	1.3	119
46	Epidemiology of <i>Malassezia</i> yeasts associated with pityriasis versicolor in Ontario, Canada. <i>Medical Mycology</i> , 2001, 39, 199-206.	0.3	119
47	Baillon, emerging clinical yeasts. <i>FEMS Yeast Research</i> , 2005, 5, 1101-1113.	1.1	119
48	New Antifungal Agents and New Formulations Against Dermatophytes. <i>Mycopathologia</i> , 2017, 182, 127-141.	1.3	119
49	An Overview of Topical Antifungal Therapy in Dermatomycoses. <i>Drugs</i> , 1998, 55, 645-674.	4.9	117
50	Onychomycosis: a critical study of techniques and criteria for confirming the etiologic significance of nondermatophytes. <i>Medical Mycology</i> , 2005, 43, 39-59.	0.3	117
51	Acitretin improves psoriasis in a dose-dependent fashion. <i>Journal of the American Academy of Dermatology</i> , 1988, 18, 655-662.	0.6	116
52	The Development of an Acne Quality of Life Scale: Reliability, Validity, and Relation to Subjective Acne Severity in Mild to Moderate Acne Vulgaris. <i>Acta Dermato-Venereologica</i> , 1998, 78, 451-456.	0.6	115
53	Side-effect profile of acitretin therapy in psoriasis. <i>Journal of the American Academy of Dermatology</i> , 1989, 20, 1088-1093.	0.6	114
54	The self-inflicted dermatoses: A critical review. <i>General Hospital Psychiatry</i> , 1987, 9, 45-52.	1.2	112

#	ARTICLE	IF	CITATIONS
55	Development and Validation of a Comprehensive Acne Severity Scale. <i>Journal of Cutaneous Medicine and Surgery</i> , 2007, 11, 211-216.	0.6	112
56	Interventions for actinic keratoses. <i>The Cochrane Library</i> , 2012, 12, CD004415.	1.5	112
57	Psoriasis and sleep disorders: A systematic review. <i>Sleep Medicine Reviews</i> , 2016, 29, 63-75.	3.8	110
58	Etiology and Management of Seborrheic Dermatitis. <i>Dermatology</i> , 2004, 208, 89-93.	0.9	107
59	Rosacea and its management: an overview. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2005, 19, 273-285.	1.3	107
60	Tinea corporis, tinea cruris, tinea nigra, and piedra. <i>Dermatologic Clinics</i> , 2003, 21, 395-400.	1.0	106
61	Molecular Differentiation of Seven <i>Malassezia</i> Species. <i>Journal of Clinical Microbiology</i> , 2000, 38, 1869-1875.	1.8	106
62	Terbinafine: An update. <i>Journal of the American Academy of Dermatology</i> , 1997, 37, 979-988.	0.6	104
63	Network meta-analysis of the outcome "participant complete clearance"™ in nonimmunosuppressed participants of eight interventions for actinic keratosis: a follow-up on a Cochrane review. <i>British Journal of Dermatology</i> , 2013, 169, 250-259.	1.4	104
64	Psoriatic Epidermal Cells Demonstrate Increased Numbers and Function of Non-Langerhans Antigen-presenting Cells. <i>Journal of Investigative Dermatology</i> , 1989, 92, 190-195.	0.3	101
65	Dermatophytoma: Recalcitrance to treatment because of existence of fungal biofilm. <i>Journal of the American Academy of Dermatology</i> , 2002, 47, 629-631.	0.6	101
66	Treatment of severe lichen planus with cyclosporine. <i>Journal of the American Academy of Dermatology</i> , 1990, 22, 64-68.	0.6	100
67	A higher prevalence of onychomycosis in psoriatics compared with non-psoriatics: a multicentre study. <i>British Journal of Dermatology</i> , 1997, 136, 786-789.	1.4	99
68	Intralesional cyclosporine in the treatment of psoriasis. <i>Journal of the American Academy of Dermatology</i> , 1990, 22, 94-100.	0.6	98
69	Drug interactions with itraconazole, fluconazole, and terbinafine and their management. <i>Journal of the American Academy of Dermatology</i> , 1999, 41, 237-249.	0.6	97
70	Alternate week and combination itraconazole and terbinafine therapy for chromoblastomycosis caused by <i>Fonsecaea pedrosoi</i> in Brazil. <i>Medical Mycology</i> , 2002, 40, 529-534.	0.3	97
71	rRNA Gene Internal Transcribed Spacer 1 and 2 Sequences of Asexual, Anthropophilic Dermatophytes Related to <i>Trichophyton rubrum</i> . <i>Journal of Clinical Microbiology</i> , 1999, 37, 4005-4011.	1.8	97
72	Terbinafine therapy may be associated with the development of psoriasis de novo or its exacerbation: Four case reports and a review of drug-induced psoriasis. <i>Journal of the American Academy of Dermatology</i> , 1997, 36, 858-862.	0.6	96

#	ARTICLE	IF	CITATIONS
73	Seborrheic dermatitis. <i>Dermatologic Clinics</i> , 2003, 21, 401-412.	1.0	96
74	Therapies for the treatment of onychomycosis. <i>Clinics in Dermatology</i> , 2013, 31, 544-554.	0.8	96
75	Sphingosine Inhibits Phorbol Ester-Induced Inflammation, Ornithine Decarboxylase Activity, and Activation of Protein Kinase C in Mouse Skin. <i>Journal of Investigative Dermatology</i> , 1988, 91, 486-491.	0.3	95
76	Tinea Capitis: An Overview with Emphasis on Management. <i>Pediatric Dermatology</i> , 1999, 16, 171-189.	0.5	94
77	Comorbidity of rosacea and depression: an analysis of the National Ambulatory Medical Care Survey and National Hospital Ambulatory Care Survey-Outpatient Department data collected by the U.S. National Center for Health Statistics from 1995 to 2002. <i>British Journal of Dermatology</i> , 2005, 153, 1176-1181.	1.4	94
78	Fusarium infections of the skin. <i>Current Opinion in Infectious Diseases</i> , 2000, 13, 121-128.	1.3	93
79	New antifungal agents. <i>Dermatologic Clinics</i> , 2003, 21, 565-576.	1.0	93
80	Itraconazole therapy is effective for pedal onychomycosis caused by some nondermatophyte molds and in mixed infection with dermatophytes and molds: A multicenter study with 36 patients. <i>Journal of the American Academy of Dermatology</i> , 1997, 36, 173-177.	0.6	92
81	Tacrolimus: a review of its use for the management of dermatoses. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2002, 16, 100-114.	1.3	92
82	Neurotic excoriations: A review and some new perspectives. <i>Comprehensive Psychiatry</i> , 1986, 27, 381-386.	1.5	91
83	Superficial fungal infections: an update on pityriasis versicolor, seborrheic dermatitis, tinea capitis, and onychomycosis. <i>Clinics in Dermatology</i> , 2003, 21, 417-425.	0.8	87
84	Evaluation of the Effectiveness of Imiquimod and 5-Fluorouracil for the Treatment of Actinic Keratosis: Critical Review and Meta-analysis of Efficacy Studies. <i>Journal of Cutaneous Medicine and Surgery</i> , 2005, 9, 209-214.	0.6	87
85	Itraconazole pulse therapy for onychomycosis and dermatomycoses: An overview. <i>Journal of the American Academy of Dermatology</i> , 1997, 37, 969-974.	0.6	85
86	Terbinafine in the Treatment of Trichophyton Tinea Capitis: A Randomized, Double-Blind, Parallel-Group, Duration-Finding Study. <i>Pediatrics</i> , 2002, 109, 602-607.	1.0	85
87	Non-dermatophyte onychomycosis. <i>Dermatologic Clinics</i> , 2003, 21, 257-268.	1.0	85
88	Tinea capitis in children: a systematic review of management. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 2264-2274.	1.3	85
89	The prevalence and management of onychomycosis in diabetic patients. <i>European Journal of Dermatology</i> , 2000, 10, 379-84.	0.3	85
90	Role of Antifungal Agents in the Treatment of Seborrheic Dermatitis. <i>American Journal of Clinical Dermatology</i> , 2004, 5, 417-422.	3.3	84

#	ARTICLE	IF	CITATIONS
91	Pityriasis versicolor. <i>Dermatologic Clinics</i> , 2003, 21, 413-429.	1.0	83
92	A favourable benefit/risk ratio with efalizumab: A review of the clinical evidence. <i>Journal of Cutaneous Medicine and Surgery</i> , 2005, 9, 10-17.	0.6	83
93	Sleep-wake disorders and dermatology. <i>Clinics in Dermatology</i> , 2013, 31, 118-126.	0.8	83
94	Viral and Nonviral Uses of Imiquimod: A Review. <i>Journal of Cutaneous Medicine and Surgery</i> , 2004, 8, 338-352.	0.6	81
95	The efficacy and safety of 5 α -reductase inhibitors in androgenetic alopecia: a network meta-analysis and benefit-risk assessment of finasteride and dutasteride. <i>Journal of Dermatological Treatment</i> , 2014, 25, 156-161.	1.1	80
96	The spectrum of cutaneous reactions associated with diltiazem: Three cases and a review of the literature. <i>Journal of the American Academy of Dermatology</i> , 1998, 38, 201-206.	0.6	79
97	Single-blind, randomized, prospective study of sequential itraconazole and terbinafine pulse compared with terbinafine pulse for the treatment of toenail onychomycosis. <i>Journal of the American Academy of Dermatology</i> , 2001, 44, 485-491.	0.6	79
98	Itraconazole for the treatment of onychomycosis. <i>International Journal of Dermatology</i> , 1998, 37, 303-308.	0.5	78
99	Systematic review of rosacea treatments. <i>Journal of the American Academy of Dermatology</i> , 2007, 56, 107-115.	0.6	78
100	New therapeutic options for onychomycosis. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 1131-1142.	0.9	77
101	A Risk-Benefit Assessment of the Newer Oral Antifungal Agents Used to Treat Onychomycosis. <i>Drug Safety</i> , 2000, 22, 33-52.	1.4	76
102	In vitro activities of posaconazole, ravuconazole, terbinafine, itraconazole and fluconazole against dermatophyte, yeast and non-dermatophyte species. <i>Medical Mycology</i> , 2005, 43, 179-185.	0.3	76
103	The role of biofilms in onychomycosis. <i>Journal of the American Academy of Dermatology</i> , 2016, 74, 1241-1246.	0.6	76
104	Ciclopirox 8% nail lacquer in the treatment of onychomycosis of the toenails in the United States. <i>Journal of the American Podiatric Medical Association</i> , 2000, 90, 495-501.	0.2	75
105	Psoriasis and psychiatry: An update. <i>General Hospital Psychiatry</i> , 1987, 9, 157-166.	1.2	74
106	Use of Eye Movement Desensitization and Reprocessing (EMDR) in the Treatment of Dermatologic Disorders. <i>Journal of Cutaneous Medicine and Surgery</i> , 2002, 6, 415-421.	0.6	73
107	A Mechanistic Model of Platelet-Rich Plasma Treatment for Androgenetic Alopecia. <i>Dermatologic Surgery</i> , 2016, 42, 1335-1339.	0.4	73
108	Perceived deprivation of social touch in psoriasis is associated with greater psychologic morbidity: an index of the stigma experience in dermatologic disorders. <i>Cutis</i> , 1998, 61, 339-42.	0.4	73

#	ARTICLE	IF	CITATIONS
109	Psychiatric Aspects of the Treatment of Mild to Moderate Facial Acne.. International Journal of Dermatology, 1990, 29, 719-721.	0.5	72
110	Lithium therapy associated with hidradenitis suppurativa: Case report and a review of the dermatologic side effects of lithium. Journal of the American Academy of Dermatology, 1995, 32, 382-386.	0.6	72
111	Increased incidence of <i>Trichophyton tonsurans</i> in Ontario, Canada between 1985 and 1996. Medical Mycology, 1998, 36, 55-60.	0.3	72
112	Single-blind, randomized, prospective study on terbinafine and itraconazole for treatment of dermatophyte toenail onychomycosis in the elderly. Journal of the American Academy of Dermatology, 2001, 44, 479-484.	0.6	72
113	CURRENT MANAGEMENT OF ONYCHOMYCOSIS. Dermatologic Clinics, 1997, 15, 121-135.	1.0	71
114	Optimal Management of Fungal Infections of the Skin, Hair, and Nails. American Journal of Clinical Dermatology, 2004, 5, 225-237.	3.3	71
115	Viral and Nonviral Uses of Imiquimod: A Review. Journal of Cutaneous Medicine and Surgery, 2004, 8, 338-352.	0.6	70
116	Meta-analysis of Randomized, Controlled Trials Comparing Particular Doses of Griseofulvin and Terbinafine for the Treatment of Tinea Capitis. Pediatric Dermatology, 2013, 30, 1-6.	0.5	70
117	The use of sulfur in dermatology. Journal of Drugs in Dermatology, 2004, 3, 427-31.	0.4	69
118	Efficacy of non-surgical treatments for androgenetic alopecia: a systematic review and network meta-analysis. Journal of the European Academy of Dermatology and Venereology, 2018, 32, 2112-2125.	1.3	68
119	Onychomycosis in children: prevalence and management.. Pediatric Dermatology, 1998, 15, 464-471.	0.5	68
120	Utility of Inoculum Counting (Walshe and English Criteria) in Clinical Diagnosis of Onychomycosis Caused by Nondermatophytic Filamentous Fungi. Journal of Clinical Microbiology, 2001, 39, 2115-2121.	1.8	67
121	The prevalence of culture-confirmed toenail onychomycosis in at-risk patient populations. Journal of the European Academy of Dermatology and Venereology, 2015, 29, 1039-1044.	1.3	66
122	Effects of insulin on renal sodium excretion.. Hypertension, 1992, 19, 178-82.	1.3	66
123	The prevalence of unsuspected onychomycosis and its causative organisms in a multicentre Canadian sample of 30 000 patients visiting physicians' offices. Journal of the European Academy of Dermatology and Venereology, 2016, 30, 1567-1572.	1.3	65
124	Erythroderma: a comparison between HIV positive and negative patients. International Journal of Dermatology, 1999, 38, 895-900.	0.5	64
125	Ungual and trans-ungual iontophoretic delivery of terbinafine for the treatment of onychomycosis. Journal of Pharmaceutical Sciences, 2009, 98, 4130-4140.	1.6	64
126	Efficacy, safety and tolerability of topical terbinafine nail solution in patients with mild-to-moderate toenail onychomycosis: results from three randomized studies using double-blind vehicle-controlled and open-label active-controlled designs. Journal of the European Academy of Dermatology and Venereology, 2013, 27, 287-294.	1.3	63

#	ARTICLE	IF	CITATIONS
127	Meta-analysis of efficacy of platelet-rich plasma therapy for androgenetic alopecia. Journal of Dermatological Treatment, 2017, 28, 55-58.	1.1	63
128	Ciclopirox: an overview. International Journal of Dermatology, 2001, 40, 305-310.	0.5	62
129	A phase I/II randomized, double-blind, placebo-controlled, dose-ranging study evaluating the efficacy, safety and pharmacokinetics of ravuconazole in the treatment of onychomycosis. Journal of the European Academy of Dermatology and Venereology, 2005, 19, 437-443.	1.3	62
130	The Rise and Fall of Oral Ketoconazole. Journal of Cutaneous Medicine and Surgery, 2015, 19, 352-357.	0.6	62
131	Sulfasalazine improves psoriasis. A double-blind analysis. Archives of Dermatology, 1990, 126, 487-493.	1.7	62
132	Onychomycosis in the Elderly. Drugs and Aging, 2000, 16, 397-407.	1.3	61
133	Efficacy of Itraconazole, Terbinafine, Fluconazole, Griseofulvin and Ketoconazole in the Treatment of <i>Scopulariopsis brevicaulis</i> Causing Onychomycosis of the Toes. Dermatology, 2001, 202, 235-238.	0.9	61
134	Onychomycosis associated with <i>Onychocola canadensis</i> : Ten case reports and a review of the literature. Journal of the American Academy of Dermatology, 1998, 39, 410-417.	0.6	60
135	Itraconazole in the Treatment of Tinea Capitis Caused by <i>Microsporum canis</i> : Experience in a Large Cohort. Pediatric Dermatology, 2004, 21, 499-502.	0.5	60
136	Depression and Skin Disease. Dermatologic Clinics, 2005, 23, 657-664.	1.0	60
137	The Impact of Onychomycosis on Quality of Life: A Systematic Review of the Available Literature. Skin Appendage Disorders, 2018, 4, 208-216.	0.5	60
138	Itraconazole pulse therapy is effective in the treatment of tinea capitis in children: an open multicentre study. British Journal of Dermatology, 1997, 137, 251-254.	1.4	58
139	Once weekly fluconazole is effective in children in the treatment of tinea capitis: a prospective, multicentre study. British Journal of Dermatology, 2000, 142, 965-968.	1.4	58
140	Prevalence of <i>Malassezia</i> species on various body sites in clinically healthy subjects representing different age groups. Medical Mycology, 2004, 42, 35-42.	0.3	58
141	Dermatophytosis: The Management of Fungal Infections. Skinmed, 2005, 4, 305-310.	0.0	58
142	Terbinafine in the treatment of dermatophyte toenail onychomycosis: a meta-analysis of efficacy for continuous and intermittent regimens. Journal of the European Academy of Dermatology and Venereology, 2013, 27, 267-272.	1.3	57
143	Minoxidil: a comprehensive review. Journal of Dermatological Treatment, 2022, 33, 1896-1906.	1.1	56
144	The use of an intermittent terbinafine regimen for the treatment of dermatophyte toenail onychomycosis. Journal of the European Academy of Dermatology and Venereology, 2009, 23, 256-262.	1.3	55

#	ARTICLE	IF	CITATIONS
145	Five-year efficacy and safety of tildrakizumab in patients with moderate-to-severe psoriasis who respond at week 28: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2)*. <i>British Journal of Dermatology</i> , 2021, 185, 323-334.	1.4	55
146	Hepatitis associated with terbinafine therapy: three case reports and a review of the literature. <i>Clinical and Experimental Dermatology</i> , 1998, 23, 64-67.	0.6	54
147	Stressful major life events are associated with a higher frequency of cutaneous sensory symptoms: an empirical study of non-clinical subjects. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2004, 18, 560-565.	1.3	54
148	Psychiatric Evaluation of the Dermatology Patient. <i>Dermatologic Clinics</i> , 2005, 23, 591-599.	1.0	54
149	Imiquimod: A Review. <i>Journal of Cutaneous Medicine and Surgery</i> , 2002, 6, 554-560.	0.6	53
150	Two feet-one hand syndrome: a retrospective multicenter survey. <i>International Journal of Dermatology</i> , 1997, 36, 658-660.	0.5	52
151	Evaluation of microdilution and disk diffusion methods for antifungal susceptibility testing of dermatophytes. <i>Medical Mycology</i> , 2007, 45, 595-602.	0.3	52
152	Platelet-Rich Plasma as a Treatment for Androgenetic Alopecia. <i>Dermatologic Surgery</i> , 2019, 45, 1262-1273.	0.4	52
153	Severe neutropenia associated with oral terbinafine therapy. <i>Journal of the American Academy of Dermatology</i> , 1998, 38, 765-767.	0.6	51
154	Itraconazole and Terbinafine Treatment of Some Nondermatophyte Molds Causing Onychomycosis of the Toes and a Review of the Literature. <i>Journal of Cutaneous Medicine and Surgery</i> , 2001, 5, 206-210.	0.6	51
155	The use of topical therapies to treat onychomycosis. <i>Dermatologic Clinics</i> , 2003, 21, 481-489.	1.0	51
156	Ciclopirox: a broad-spectrum antifungal with antibacterial and anti-inflammatory properties. <i>International Journal of Dermatology</i> , 2004, 43, 3-8.	0.5	51
157	Divergence of Demographic Factors Associated with Clinical Severity Compared with Quality of Life Impact in Acne. <i>Journal of Cutaneous Medicine and Surgery</i> , 2008, 12, 235-242.	0.6	51
158	Diagnosing onychomycosis. <i>Clinics in Dermatology</i> , 2013, 31, 540-543.	0.8	51
159	Systematic Review of Oral Treatments for Seborrheic Dermatitis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2014, 28, 16-26.	1.3	51
160	Management of diaper dermatitis. <i>International Journal of Dermatology</i> , 2004, 43, 830-834.	0.5	50
161	Onychomycosis in Children: A Brief Overview with Treatment Strategies. <i>Pediatric Dermatology</i> , 2004, 21, 74-79.	0.5	50
162	Efficacy of tofacitinib in treatment of alopecia universalis in two patients. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016, 30, 1373-1378.	1.3	50

#	ARTICLE	IF	CITATIONS
163	Cyclosporine in the treatment of psoriatic arthritis. Archives of Dermatology, 1989, 125, 507-510.	1.7	50
164	Dissatisfaction with skin appearance among patients with eating disorders and non-clinical controls. British Journal of Dermatology, 2001, 145, 110-113.	1.4	49
165	The Growing Problem of Antifungal Resistance in Onychomycosis and Other Superficial Mycoses. American Journal of Clinical Dermatology, 2021, 22, 149-157.	3.3	49
166	The Use of Itraconazole to Treat Cutaneous Fungal Infections in Children. Dermatology, 1999, 199, 248-252.	0.9	48
167	Evaluation of cutaneous body image dissatisfaction in the dermatology patient. Clinics in Dermatology, 2013, 31, 72-79.	0.8	48
168	Antifungal Treatment for Pityriasis Versicolor. Journal of Fungi (Basel, Switzerland), 2015, 1, 13-29.	1.5	48
169	The new oral antifungal agents for onychomycosis of the toenails. Journal of the European Academy of Dermatology and Venereology, 1999, 13, 1-13.	1.3	47
170	Calcipotriol plus Betamethasone Dipropionate Gel Compared with Tacalcitol Ointment and the Gel Vehicle Alone in Patients with Psoriasis Vulgaris: A Randomized, Controlled Clinical Trial. Dermatology, 2011, 222, 148-156.	0.9	47
171	A randomized study comparing the combination of nbUVB and etanercept to etanercept monotherapy in patients with psoriasis who do not exhibit an excellent response after 12 weeks of etanercept. Journal of Dermatological Treatment, 2012, 23, 261-267.	1.1	47
172	Peripheral edema due to nifedipine-itraconazole interaction: a case report. Archives of Dermatology, 1996, 132, 350-352.	1.7	47
173	Cigarette smoking in men may be a risk factor for increased severity of psoriasis of the extremities. British Journal of Dermatology, 1996, 135, 859-860.	1.4	46
174	A higher prevalence of onychomycosis in psoriatics compared with non-psoriatics: a multicentre study. British Journal of Dermatology, 1997, 136, 786-789.	1.4	46
175	Ciclopirox nail lacquer solution 8% in the 21st century. Journal of the American Academy of Dermatology, 2000, 43, S96-S102.	0.6	45
176	Photodynamic Therapy and Topical Aminolevulinic Acid. American Journal of Clinical Dermatology, 2003, 4, 699-708.	3.3	45
177	Efficacy of Itraconazole in the Prophylactic Treatment of Pityriasis (Tinea) Versicolor. Archives of Dermatology, 2002, 138, 69-73.	1.7	44
178	Hepatic Safety of Itraconazole. Journal of Cutaneous Medicine and Surgery, 2002, 6, 210-213.	0.6	43
179	The management of actinic keratoses in the United States with topical fluorouracil: a pharmaco-economic evaluation. Cutis, 2002, 70, 30-6.	0.4	43
180	Development and Validation of a Scale for Acne Scar Severity (SCAR-S) of the Face and Trunk. Journal of Cutaneous Medicine and Surgery, 2010, 14, 156-160.	0.6	42

#	ARTICLE	IF	CITATIONS
181	Systemic Antifungals to Treat Onychomycosis in Children: A Systematic Review. <i>Pediatric Dermatology</i> , 2013, 30, 294-302.	0.5	42
182	Topical Therapy for Toenail Onychomycosis: An Evidence-Based Review. <i>American Journal of Clinical Dermatology</i> , 2014, 15, 489-502.	3.3	42
183	Drug safety assessment of oral formulations of ketoconazole. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 325-334.	1.0	42
184	Treatments of tinea pedis. <i>Dermatologic Clinics</i> , 2003, 21, 431-462.	1.0	41
185	Medically unexplained cutaneous sensory symptoms may represent somatoform dissociation: An empirical study. <i>Journal of Psychosomatic Research</i> , 2006, 60, 131-136.	1.2	41
186	Evidence-based optimal fluconazole dosing regimen for onychomycosis treatment. <i>Journal of Dermatological Treatment</i> , 2013, 24, 75-80.	1.1	41
187	Update on current approaches to diagnosis and treatment of onychomycosis. <i>Expert Review of Anti-Infective Therapy</i> , 2018, 16, 929-938.	2.0	41
188	Topical Cyclosporine A Inhibits the Phorbol Ester Induced Hyperplastic Inflammatory Response but not Protein Kinase C Activation in Mouse Epidermis.. <i>Journal of Investigative Dermatology</i> , 1989, 93, 379-386.	0.3	40
189	Effects of cyclosporine on immunologic mechanisms in psoriasis. <i>Journal of the American Academy of Dermatology</i> , 1990, 23, 1318-1328.	0.6	40
190	Detection of Xanthomegnin in Epidermal Materials Infected with <i>Trichophyton rubrum</i> . <i>Journal of Investigative Dermatology</i> , 2000, 115, 901-905.	0.3	40
191	Fast and sensitive detection of <i>Trichophyton rubrum</i> DNA from the nail samples of patients with onychomycosis by a double-round polymerase chain reaction-based assay. <i>British Journal of Dermatology</i> , 2007, 157, 698-703.	1.4	40
192	The Efficacy of Platelet-Rich Plasma in the Field of Hair Restoration and Facial Aestheticsâ€”A Systematic Review and Meta-analysis. <i>Journal of Cutaneous Medicine and Surgery</i> , 2019, 23, 185-203.	0.6	40
193	Psychotropic drugs in dermatology. <i>Journal of the American Academy of Dermatology</i> , 1986, 14, 633-645.	0.6	39
194	TERBINAFINE IN THE TREATMENT OF MAJOCCHI'S GRANULOMA. <i>International Journal of Dermatology</i> , 1995, 34, 489-489.	0.5	39
195	Factors that may affect the response of onychomycosis to oral antifungal therapy. <i>Australasian Journal of Dermatology</i> , 1998, 39, 222-224.	0.4	39
196	Ciclopirox for the treatment of superficial fungal infections: a review. <i>International Journal of Dermatology</i> , 2003, 42, 3-9.	0.5	39
197	Efficacy and safety of itraconazole use in children. <i>Dermatologic Clinics</i> , 2003, 21, 521-535.	1.0	39
198	The use of oral antifungal agents to treat onychomycosis. <i>Dermatologic Clinics</i> , 2003, 21, 469-479.	1.0	39

#	ARTICLE	IF	CITATIONS
199	Diagnosing Onychomycosis. <i>Dermatologic Clinics</i> , 2006, 24, 365-369.	1.0	39
200	Dermatophytes: Diagnosis and treatment. <i>Journal of the American Academy of Dermatology</i> , 2006, 54, 1050-1055.	0.6	39
201	Topical Treatment of Facial Seborrheic Dermatitis: A Systematic Review. <i>American Journal of Clinical Dermatology</i> , 2017, 18, 193-213.	3.3	39
202	Global perspectives for the management of onychomycosis. <i>International Journal of Dermatology</i> , 2019, 58, 1118-1129.	0.5	39
203	Economic Evaluation of Antifungal Agents in the Treatment of Toenail Onychomycosis in Germany. <i>Dermatology</i> , 1996, 193, 239-244.	0.9	38
204	Hypersensitivity reaction to terbinafine. <i>Journal of the American Academy of Dermatology</i> , 1997, 36, 1018-1019.	0.6	38
205	Azelaic acid (15% gel) in the treatment of acne rosacea. <i>International Journal of Dermatology</i> , 2007, 46, 533-538.	0.5	38
206	A critical review of improvement rates for laser therapy used to treat toenail onychomycosis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 1111-1118.	1.3	38
207	Evidence for biofilms in onychomycosis. <i>Giornale Italiano Di Dermatologia E Venereologia</i> , 2019, 154, 50-55.	0.8	38
208	Antifungal agents: an overview. Part I. <i>Journal of the American Academy of Dermatology</i> , 1994, 30, 677-98; quiz 698-700.	0.6	38
209	An evaluation of intermittent therapies used to treat onychomycosis and other dermatomycoses with the oral antifungal agents. <i>International Journal of Dermatology</i> , 2000, 39, 401-411.	0.5	37
210	Comparative efficacies of commonly used disinfectants and antifungal pharmaceutical spray preparations against dermatophytic fungi. <i>Medical Mycology</i> , 2001, 39, 321-328.	0.3	37
211	Therapies for Onychomycosis: A Review. <i>Dermatologic Clinics</i> , 2006, 24, 375-379.	1.0	37
212	Pulse itraconazole vs. continuous terbinafine for the treatment of dermatophyte toenail onychomycosis in patients with diabetes mellitus. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2006, 20, 1188-1193.	1.3	37
213	Depression Modulates Pruritus Perception: A Study of Pruritus in Psoriasis, Atopic Dermatitis and Chronic Idiopathic Urticaria. <i>Annals of the New York Academy of Sciences</i> , 2006, 885, 394-395.	1.8	37
214	Molecular Determination of Mixed Infections of Dermatophytes and Nondermatophyte Molds in Individuals with Onychomycosis. <i>Journal of the American Podiatric Medical Association</i> , 2014, 104, 330-336.	0.2	37
215	Psychological Factors Affecting Self-Excoriative Behavior in Women With Mild-to-Moderate Facial Acne Vulgaris. <i>Psychosomatics</i> , 1996, 37, 127-130.	2.5	36
216	Quality of life of psoriasis patients. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2000, 14, 241-242.	1.3	36

#	ARTICLE	IF	CITATIONS
217	Treatment of tinea capitis with itraconazole capsule pulse therapy. Journal of the American Academy of Dermatology, 1998, 39, 216-219.	0.6	35
218	Variation in Restriction Fragment Length Polymorphisms among Serial Isolates from Patients with Trichophyton rubrum Infection. Journal of Clinical Microbiology, 2001, 39, 3260-3266.	1.8	35
219	Fungicidal activities of commonly used disinfectants and antifungal pharmaceutical spray preparations against clinical strains of <i>Aspergillus</i> and <i>Candida</i> species. Medical Mycology, 2002, 40, 201-208.	0.3	35
220	Onychomycosis: strategies to improve efficacy and reduce recurrence. Journal of the European Academy of Dermatology and Venereology, 2002, 16, 579-586.	1.3	35
221	Evaluation of in vitro Resistance in Patients with Onychomycosis Who Fail Antifungal Therapy. Dermatology, 2003, 207, 375-380.	0.9	35
222	Naftifine: A Review. Journal of Cutaneous Medicine and Surgery, 2008, 12, 51-58.	0.6	35
223	A double-blind, randomized, placebo-controlled trial of eutectic lidocaine/prilocaine cream 5% (EMLA) for analgesia prior to cryotherapy of warts in children and adults.. Pediatric Dermatology, 1998, 15, 129-133.	0.5	35
224	Relative Efficacy of Minoxidil and the 5- α Reductase Inhibitors in Androgenetic Alopecia Treatment of Male Patients. JAMA Dermatology, 2022, 158, 266.	2.0	35
225	DERMATITIS ARTEFACTA AND SEXUAL ABUSE. International Journal of Dermatology, 1993, 32, 825-826.	0.5	34
226	Oral antifungal agents for onychomycosis. Lancet, The, 1998, 351, 541-542.	6.3	34
227	Pharmacoeconomic analysis of ciclopirox nail lacquer solution 8% and the new oral antifungal agents used to treat dermatophyte toe onychomycosis in the United States. Journal of the American Academy of Dermatology, 2000, 43, S81-S95.	0.6	34
228	Tinea Capitis in Kwa-Zulu Natal, South Africa. Pediatric Dermatology, 2004, 21, 444-447.	0.5	34
229	Treatment of Onychomycosis: Pros and Cons of Antifungal Agents. Journal of Cutaneous Medicine and Surgery, 2004, 8, 25-30.	0.6	34
230	Network Meta-Analysis of Onychomycosis Treatments. Skin Appendage Disorders, 2015, 1, 74-81.	0.5	34
231	A Critical Assessment of the Evidence for Low-Level Laser Therapy in the Treatment of Hair Loss. Dermatologic Surgery, 2017, 43, 188-197.	0.4	34
232	The use of high-frequency ultrasound as a method of assessing the severity of a plaque of psoriasis. Archives of Dermatology, 1996, 132, 658-662.	1.7	34
233	ORAL ANTIFUNGAL DRUG INTERACTIONS. Dermatologic Clinics, 1997, 15, 535-544.	1.0	33
234	Candida infection of the nail: role of Candida as a primary or secondary pathogen. International Journal of Dermatology, 1998, 37, 904-907.	0.5	33

#	ARTICLE	IF	CITATIONS
235	Itraconazole pulse therapy is effective in the treatment of Majocchi's granuloma: a clinical and pharmacokinetic evaluation and implications for possible effectiveness in tinea capitis. <i>Clinical and Experimental Dermatology</i> , 1998, 23, 103-108.	0.6	33
236	How to improve cure rates for the management of onychomycosis. <i>Dermatologic Clinics</i> , 2003, 21, 499-505.	1.0	33
237	Suicidal behaviors in the dermatology patient. <i>Clinics in Dermatology</i> , 2017, 35, 302-311.	0.8	33
238	Nondermatophyte causes of onychomycosis and superficial mycoses. <i>Current Topics in Medical Mycology</i> , 1996, 7, 87-97.	0.8	33
239	PSYCHOSOMATIC STUDY OF SELF-EXCORIATIVE BEHAVIOR AMONG MALE ACNE PATIENTS: PRELIMINARY OBSERVATIONS. <i>International Journal of Dermatology</i> , 1994, 33, 846-848.	0.5	32
240	Onychomycosis: An evaluation of three sampling methods. <i>Journal of the American Academy of Dermatology</i> , 1998, 39, 1015-1017.	0.6	32
241	Itraconazole is Effective in the Treatment of Tinea Capitis Caused by <i>Microsporum Canis</i> . <i>Pediatric Dermatology</i> , 2001, 18, 519-522.	0.5	32
242	Fungal infections in immunocompromised patients. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2003, 17, 1-2.	1.3	32
243	The efficacy and safety of terbinafine in children. <i>Dermatologic Clinics</i> , 2003, 21, 511-520.	1.0	32
244	Cutaneous body image dissatisfaction and suicidal ideation: Mediation by interpersonal sensitivity. <i>Journal of Psychosomatic Research</i> , 2013, 75, 55-59.	1.2	32
245	Systematic Review of Systemic Treatments for Tinea Versicolor and Evidence-Based Dosing Regimen Recommendations. <i>Journal of Cutaneous Medicine and Surgery</i> , 2014, 18, 79-90.	0.6	32
246	Confirmatory Testing Prior to Initiating Onychomycosis Therapy Is Cost-Effective. <i>Journal of Cutaneous Medicine and Surgery</i> , 2018, 22, 129-141.	0.6	32
247	The Protean <i>Acremonium</i> . <i>A. sclerotigenum/egyptiacum</i> : Revision, Food Contaminant, and Human Disease. <i>Microorganisms</i> , 2018, 6, 88.	1.6	32
248	High prevalence of mixed infections in global onychomycosis. <i>PLoS ONE</i> , 2020, 15, e0239648.	1.1	32
249	The use of terbinafine in the treatment of onychomycosis in adults and special populations: a review of the evidence. <i>Journal of Drugs in Dermatology</i> , 2005, 4, 302-8.	0.4	32
250	Meta-analysis: griseofulvin efficacy in the treatment of tinea capitis. <i>Journal of Drugs in Dermatology</i> , 2008, 7, 369-72.	0.4	32
251	Itraconazole oral solution for the treatment of tinea capitis. <i>British Journal of Dermatology</i> , 1998, 139, 104-106.	1.4	31
252	The Implications and Management of Drug Interactions with Itraconazole, Fluconazole and Terbinafine. <i>Dermatology</i> , 2000, 201, 196-203.	0.9	31

#	ARTICLE	IF	CITATIONS
253	Itraconazole pulse therapy for the treatment of Candida onychomycosis. Journal of the European Academy of Dermatology and Venereology, 2001, 15, 112-115.	1.3	31
254	Pharmacotherapy of onychomycosis. Expert Opinion on Pharmacotherapy, 2005, 6, 609-624.	0.9	31
255	Terbinafine pulse therapy is effective in tinea capitis.. Pediatric Dermatology, 1998, 15, 56-58.	0.5	31
256	Onychomycosis: classification and diagnosis. Journal of Drugs in Dermatology, 2004, 3, 51-6.	0.4	31
257	Onychomycosis therapy: past, present, future. Journal of Drugs in Dermatology, 2010, 9, 1109-13.	0.4	31
258	Perceived touch deprivation and body image: some observations among eating disordered and non-clinical subjects. Journal of Psychosomatic Research, 1995, 39, 459-464.	1.2	30
259	Pharmacoeconomic Analysis of Oral Antifungal Therapies Used to Treat Dermatophyte Onychomycosis of the Toenails. Pharmacoeconomics, 1998, 13, 243-256.	1.7	30
260	Heparin-Induced Thrombocytopenia. Annals of Pharmacotherapy, 1998, 32, 55-59.	0.9	30
261	Comment & controversy. Clinics in Dermatology, 2001, 19, 360-363.	0.8	30
262	The efficacy and safety of terbinafine in children. Journal of the European Academy of Dermatology and Venereology, 2003, 17, 627-640.	1.3	30
263	Evaluation of the Effectiveness of Imiquimod and 5-Fluorouracil for the Treatment of Actinic Keratosis: Critical Review and Meta-Analysis of Efficacy Studies. Journal of Cutaneous Medicine and Surgery, 2005, 9, 209-214.	0.6	30
264	Recent advances in therapies for onychomycosis and its management. F1000Research, 2019, 8, 968.	0.8	30
265	Ciclopirox topical solution, 8% combined with oral terbinafine to treat onychomycosis: a randomized, evaluator-blinded study. Journal of Drugs in Dermatology, 2005, 4, 481-5.	0.4	30
266	Imiquimod: A Review. Journal of Cutaneous Medicine and Surgery, 2002, 6, 554-560.	0.6	29
267	The diagnosis of nondermatophyte mold onychomycosis. International Journal of Dermatology, 2003, 42, 272-273.	0.5	29
268	Ciclopirox 1% shampoo for the treatment of seborrheic dermatitis. International Journal of Dermatology, 2006, 45, 66-69.	0.5	29
269	<i>In vitro</i> pharmacodynamic characteristics of griseofulvin against dermatophyte isolates of <i>Trichophyton tonsurans</i> from tinea capitis patients. Medical Mycology, 2009, 47, 796-801.	0.3	29
270	Medical devices for the treatment of onychomycosis. Dermatologic Therapy, 2012, 25, 574-581.	0.8	29

#	ARTICLE	IF	CITATIONS
271	Sanitization of Contaminated Footwear from Onychomycosis Patients Using Ozone Gas: A Novel Adjunct Therapy for Treating Onychomycosis and Tinea Pedis?. <i>Journal of Cutaneous Medicine and Surgery</i> , 2013, 17, 243-249.	0.6	29
272	Novel investigational therapies for onychomycosis: an update. <i>Expert Opinion on Investigational Drugs</i> , 2016, 25, 297-305.	1.9	29
273	Itraconazole for the treatment of tinea pedis: A dosage of 400 mg/day given for 1 week is similar in efficacy to 100 or 200 mg/day given for 2 to 4 weeks. <i>Journal of the American Academy of Dermatology</i> , 1997, 36, 789-792.	0.6	28
274	Combined distal and lateral subungual and white superficial onychomycosis in the toenails. <i>Journal of the American Academy of Dermatology</i> , 1999, 41, 938-944.	0.6	28
275	Hepatic Safety of Itraconazole. <i>Journal of Cutaneous Medicine and Surgery</i> , 2002, 6, 210-213.	0.6	28
276	Psoriatic Nail Disease: Quality of Life and Treatment. <i>Journal of Cutaneous Medicine and Surgery</i> , 2009, 13, S102-S106.	0.6	28
277	New pharmacotherapy for the treatment of onychomycosis: an update. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 227-236.	0.9	28
278	Tavaborole â€œ a treatment for onychomycosis of the toenails. <i>Expert Review of Clinical Pharmacology</i> , 2016, 9, 1145-1152.	1.3	28
279	Onychomycosis in children: Safety and efficacy of antifungal agents. <i>Pediatric Dermatology</i> , 2018, 35, 552-559.	0.5	28
280	Monotherapy for toenail onychomycosis: a systematic review and network meta-analysis. <i>British Journal of Dermatology</i> , 2020, 182, 287-299.	1.4	28
281	A Randomized, Double-Blind, Multicenter, Parallel Group Study to Compare Relative Efficacies of the Topical Gels 3% Erythromycin/5% Benzoyl Peroxide and 0.025% Tretinoin/Erythromycin 4% in the Treatment of Moderate Acne Vulgaris of the Face. <i>Journal of Cutaneous Medicine and Surgery</i> , 2003, 7, 31-37.	0.6	27
282	A Review of the Use of Infliximab to Manage Cutaneous Dermatoses. <i>Journal of Cutaneous Medicine and Surgery</i> , 2004, 8, 77-89.	0.6	27
283	Assessing finasteride-associated sexual dysfunction using the <scp>FAERS</scp> database. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 1069-1075.	1.3	27
284	A Practical Guide to Curing Onychomycosis: How to Maximize Cure at the Patient, Organism, Treatment, and Environmental Level. <i>American Journal of Clinical Dermatology</i> , 2019, 20, 123-133.	3.3	27
285	Onychomycosis: Strategies to Minimize Recurrence. <i>Journal of Drugs in Dermatology</i> , 2016, 15, 279-82.	0.4	27
286	Early onset (< 40 years age) psoriasis is comorbid with greater psychopathology than late onset psoriasis: a study of 137 patients.. <i>Acta Dermato-Venereologica</i> , 1996, 76, 464-466.	0.6	27
287	Short-term Changes in Renal Function, Blood Pressure, and Electrolyte Levels in Patients Receiving Cyclosporine for Dermatologic Disorders. <i>Archives of Internal Medicine</i> , 1991, 151, 356.	4.3	26
288	Recurrences of Dermatophyte Toenail Onychomycosis during Long-Term Follow-up after Successful Treatments with Mono- and Combined Therapy of Terbinafine and Itraconazole. <i>Journal of Cutaneous Medicine and Surgery</i> , 2013, 17, 201-206.	0.6	26

#	ARTICLE	IF	CITATIONS
289	Ingenol Mebutate: A Promising Treatment for Actinic Keratoses and Nonmelanoma Skin Cancers. <i>Journal of Cutaneous Medicine and Surgery</i> , 2013, 17, 173-179.	0.6	26
290	Tavaborole (AN-2690) for the treatment of onychomycosis of the toenail in adults. <i>Expert Review of Anti-Infective Therapy</i> , 2014, 12, 735-742.	2.0	26
291	A critical appraisal of once-daily topical luliconazole for the treatment of superficial fungal infections. <i>Infection and Drug Resistance</i> , 2016, 9, 1.	1.1	26
292	An open comparative study of nail drilling as adjunctive treatment for toenail onychomycosis. <i>Journal of Dermatological Treatment</i> , 2016, 27, 480-483.	1.1	26
293	Posttraumatic stress disorder (PTSD) and the dermatology patient. <i>Clinics in Dermatology</i> , 2017, 35, 260-266.	0.8	26
294	Self-induced dermatoses: A great imitator. <i>Clinics in Dermatology</i> , 2019, 37, 268-277.	0.8	26
295	Hypersensitivity syndrome reaction to oral terbinafine. <i>Australasian Journal of Dermatology</i> , 1998, 39, 171-172.	0.4	25
296	Safety of Itraconazole in Diabetic Patients. <i>Dermatology</i> , 1999, 198, 382-384.	0.9	25
297	Itraconazole and Terbinafine Treatment of Some Nondermatophyte Molds Causing Onychomycosis of the Toes and a Review of the Literature. <i>Journal of Cutaneous Medicine and Surgery</i> , 2001, 5, 206-210.	0.6	25
298	Pityriasis versicolor: a review of pharmacological treatment options. <i>Expert Opinion on Pharmacotherapy</i> , 2005, 6, 165-178.	0.9	25
299	Chronic idiopathic urticaria and post-traumatic stress disorder (PTSD): An under-recognized comorbidity. <i>Clinics in Dermatology</i> , 2012, 30, 351-354.	0.8	25
300	Onychomycosis Infections. <i>Journal of the American Podiatric Medical Association</i> , 2017, 107, 280-286.	0.2	25
301	Nondermatophyte mould onychomycosis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 1628-1641.	1.3	25
302	Topical cyclosporine A inhibits the phorbol ester induced hyperplastic inflammatory response but not protein kinase C activation in mouse epidermis. <i>Journal of Investigative Dermatology</i> , 1989, 93, 379-386.	0.3	24
303	Olanzapine May Be an Effective Adjunctive Therapy in the Management of <i>Acne Excoriata</i> : A Case Report. <i>Journal of Cutaneous Medicine and Surgery</i> , 2001, 5, 25-27.	0.6	24
304	A practical approach to the assessment of psychosocial and psychiatric comorbidity in the dermatology patient. <i>Clinics in Dermatology</i> , 2013, 31, 57-61.	0.8	24
305	Pityriasis versicolor: an update on pharmacological treatment options. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 1707-1713.	0.9	24
306	Management of Onychomycosis in Canada in 2014. <i>Journal of Cutaneous Medicine and Surgery</i> , 2015, 19, 260-273.	0.6	24

#	ARTICLE	IF	CITATIONS
307	A retrospective chart review of the clinical efficacy of Nd:YAG 1064-nm laser for toenail onychomycosis. <i>Journal of Dermatological Treatment</i> , 2015, 26, 376-378.	1.1	24
308	Treating Alopecia Areata: Current Practices Versus New Directions. <i>American Journal of Clinical Dermatology</i> , 2017, 18, 67-75.	3.3	24
309	Efficacy of non-surgical treatments for androgenetic alopecia in men and women: a systematic review with network meta-analyses, and an assessment of evidence quality. <i>Journal of Dermatological Treatment</i> , 2022, 33, 62-72.	1.1	24
310	Oral cyclosporine in the treatment of inflammatory and noninflammatory dermatoses. A clinical and immunopathologic analysis. <i>Archives of Dermatology</i> , 1990, 126, 339-50.	1.7	24
311	A higher prevalence of onychomycosis in psoriatics compared with non-psoriatics: a multicentre study. <i>British Journal of Dermatology</i> , 1997, 136, 786-9.	1.4	24
312	Onychomycosis: strategies to reduce failure and recurrence. <i>Cutis</i> , 1998, 62, 189-91.	0.4	24
313	Pruritus associated with nocturnal awakenings: Organic or psychogenic?. <i>Journal of the American Academy of Dermatology</i> , 1989, 21, 479-484.	0.6	23
314	Interaction between Terbinafine and Warfarin. <i>Dermatology</i> , 1998, 196, 266-267.	0.9	23
315	Arthroconidial formation in <i>Trichophyton raubitschekii</i> . Arthrokonidienbildung bei <i>Trichophyton raubitschekii</i> . <i>Mycoses</i> , 2003, 46, 304-310.	1.8	23
316	Effect of Quality of Life Impact and Clinical Severity on Adherence to Topical Acne Treatment. <i>Journal of Cutaneous Medicine and Surgery</i> , 2009, 13, 204-208.	0.6	23
317	Improved efficacy in onychomycosis therapy. <i>Clinics in Dermatology</i> , 2013, 31, 555-563.	0.8	23
318	Topical minocycline foam for moderate to severe acne vulgaris: Phase 2 randomized double-blind, vehicle-controlled study results. <i>Journal of the American Academy of Dermatology</i> , 2016, 74, 1251-1252.	0.6	23
319	Onychomycosis: predisposed populations and some predictors of suboptimal response to oral antifungal agents. <i>European Journal of Dermatology</i> , 1999, 9, 633-8.	0.3	23
320	Onychomycosis: an overview. <i>Journal of Drugs in Dermatology</i> , 2013, 12, s96-103.	0.4	23
321	A Randomized, Double-Blind, Multicenter, Parallel Group Study to Compare Relative Efficacies of the Topical Gels 3% Erythromycin/5% Benzoyl Peroxide and 0.025% Tretinoin/Erythromycin 4% in the Treatment of Moderate Acne Vulgaris of the Face. <i>Journal of Cutaneous Medicine and Surgery</i> , 2003, 7, 31-37.	0.6	22
322	The use of fluconazole to treat superficial fungal infections in children. <i>Dermatologic Clinics</i> , 2003, 21, 537-542.	1.0	22
323	Cutaneous Body Image: Empirical Validation of a Dermatologic Construct. <i>Journal of Investigative Dermatology</i> , 2004, 123, 405-406.	0.3	22
324	Increased frequency of Attention Deficit Hyperactivity Disorder (ADHD) in acne versus dermatologic controls: analysis of an epidemiologic database from the US. <i>Journal of Dermatological Treatment</i> , 2014, 25, 115-118.	1.1	22

#	ARTICLE	IF	CITATIONS
325	Pathogenesis, Clinical Signs and Treatment Recommendations in Brittle Nails: A Review. <i>Dermatology and Therapy</i> , 2020, 10, 15-27.	1.4	22
326	Lymphocytic infiltrates of the skin in association with cyclosporine therapy. <i>Journal of the American Academy of Dermatology</i> , 1990, 23, 1137-1141.	0.6	21
327	Clinical and Economic Factors in the Treatment of Onychomycosis. <i>Pharmacoeconomics</i> , 1996, 9, 307-320.	1.7	21
328	Intermittent short duration therapy with fluconazole is effective for tinea capitis. <i>British Journal of Dermatology</i> , 1999, 141, 304-306.	1.4	21
329	Pharmacoeconomic analysis of the new oral antifungal agents used to treat toenail onychomycosis in the USA. <i>International Journal of Dermatology</i> , 1999, 38, 53-64.	0.5	21
330	Newly Approved Laser Systems for Onychomycosis. <i>Journal of the American Podiatric Medical Association</i> , 2012, 102, 428-430.	0.2	21
331	Investigational drugs for onychomycosis. <i>Expert Opinion on Investigational Drugs</i> , 2014, 23, 97-106.	1.9	21
332	The use of low-level light therapy in the treatment of androgenetic alopecia and female pattern hair loss. <i>Journal of Dermatological Treatment</i> , 2014, 25, 162-163.	1.1	21
333	Increased Risk of Tinea Pedis and Onychomycosis Among Swimming Pool Employees in Netanya Area, Israel. <i>Mycopathologia</i> , 2016, 181, 851-856.	1.3	21
334	The future of lasers in onychomycosis. <i>Journal of Dermatological Treatment</i> , 2016, 27, 167-172.	1.1	21
335	Common drug-drug interactions in antifungal treatments for superficial fungal infections. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2018, 14, 387-398.	1.5	21
336	Antibiofilm Treatment for Onychomycosis and Chronic Fungal Infections. <i>Skin Appendage Disorders</i> , 2018, 4, 136-140.	0.5	21
337	Topical and device-based treatments for fungal infections of the toenails. <i>The Cochrane Library</i> , 2020, 1, CD012093.	1.5	21
338	Platelet-Rich Plasma for Hair Loss. , 2021, , 71-82.		21
339	Antifungal resistance in superficial mycoses. <i>Journal of Dermatological Treatment</i> , 2022, 33, 1888-1895.	1.1	21
340	Use of Eye Movement Desensitization and Reprocessing (EMDR) in the Treatment of Dermatologic Disorders. <i>Journal of Cutaneous Medicine and Surgery</i> , 2002, 6, 415-421.	0.6	20
341	Evaluation of the efficacy of ciclopirox 0.77% gel in the treatment of tinea pedis interdigitalis (dermatophytosis complex) in a randomized, double-blind, placebo-controlled trial. <i>International Journal of Dermatology</i> , 2005, 44, 590-593.	0.5	20
342	Therapies for Onychomycosis. <i>Journal of the American Podiatric Medical Association</i> , 2015, 105, 357-366.	0.2	20

#	ARTICLE	IF	CITATIONS
343	The development of green vision in association with terbinafine therapy. Archives of Dermatology, 1996, 132, 845-846.	1.7	20
344	The efficacy and safety of efinaconazole 10% solution for treatment of mild to moderate onychomycosis: a pooled analysis of two phase 3 randomized trials. Journal of Drugs in Dermatology, 2014, 13, 815-20.	0.4	20
345	Itraconazole pulse therapy is effective in dermatophyte onychomycosis of the toenail: a double-blind placebo-controlled study. Journal of Dermatological Treatment, 2000, 11, 33-37.	1.1	19
346	Do Genetic Mutations and Genotypes Contribute to Onychomycosis?. Dermatology, 2014, 228, 207-210.	0.9	19
347	Current Concepts in Psychodermatology. Current Psychiatry Reports, 2014, 16, 449.	2.1	19
348	<i>Trichophyton rubrum</i> DNA strain switching increases in patients with onychomycosis failing antifungal treatments. British Journal of Dermatology, 2015, 172, 74-80.	1.4	19
349	Improving Cure Rates in Onychomycosis. Journal of Cutaneous Medicine and Surgery, 2016, 20, 517-531.	0.6	19
350	Dissociation and conversion symptoms in dermatology. Clinics in Dermatology, 2017, 35, 267-272.	0.8	19
351	Topical antifungal treatment prevents recurrence of toenail onychomycosis following cure. Dermatologic Therapy, 2017, 30, e12545.	0.8	19
352	Use of antipsychotic drugs in dermatology. Clinics in Dermatology, 2018, 36, 765-773.	0.8	19
353	Itraconazole oral solution for the treatment of onychomycosis.. Pediatric Dermatology, 1998, 15, 472-474.	0.5	19
354	Microneedling for Hair Loss. Journal of Cosmetic Dermatology, 2022, 21, 108-117.	0.8	19
355	Fluoxetine is an effective treatment for neurotic excoriations: case report. Cutis, 1993, 51, 386-7.	0.4	19
356	5% Minoxidil: treatment for female pattern hair loss. Skin Therapy Letter, 2014, 19, 5-7.	0.3	19
357	Bulimia Nervosa and Acne May be Related: A Case Report*. Canadian Journal of Psychiatry, 1992, 37, 58-61.	0.9	18
358	Treatment of Onychomycosis: Pros and Cons of Antifungal Agents. Journal of Cutaneous Medicine and Surgery, 2004, 8, 25-30.	0.6	18
359	Diagnosis of <i>Trichophyton rubrum</i> from Onychomycotic Nail Samples Using Polymerase Chain Reaction and Calcofluor White Microscopy. Journal of the American Podiatric Medical Association, 2008, 98, 224-228.	0.2	18
360	ISA247: Quality of Life Results from a Phase II, Randomized, Placebo-Controlled Study. Journal of Cutaneous Medicine and Surgery, 2008, 12, 268-275.	0.6	18

#	ARTICLE	IF	CITATIONS
361	Laser Therapy for Onychomycosis. <i>Journal of Cutaneous Medicine and Surgery</i> , 2013, 17, 301-307.	0.6	18
362	Potential role of tavaborole for the treatment of onychomycosis. <i>Future Microbiology</i> , 2014, 9, 1243-1250.	1.0	18
363	Ozone gas effectively kills laboratory strains of <i>Trichophyton rubrum</i> and <i>Trichophyton mentagrophytes</i> using an <i>in vitro</i> test system. <i>Journal of Dermatological Treatment</i> , 2014, 25, 251-255.	1.1	18
364	Dissatisfaction with cutaneous body image is directly correlated with insomnia severity: A prospective study in a non-clinical sample. <i>Journal of Dermatological Treatment</i> , 2015, 26, 193-197.	1.1	18
365	Routes of drug delivery into the nail apparatus: Implications for the efficacy of topical nail solutions in onychomycosis. <i>Journal of Dermatological Treatment</i> , 2016, 27, 2-4.	1.1	18
366	Fungal Diversity and Onychomycosis. <i>Journal of the American Podiatric Medical Association</i> , 2019, 109, 57-63.	0.2	18
367	Finasteride for androgenetic alopecia is not associated with sexual dysfunction: a survey-based, single-centre, controlled study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 1393-1397.	1.3	18
368	A Paradigm Shift in the Treatment and Management of Onychomycosis. <i>Skin Appendage Disorders</i> , 2021, 7, 351-358.	0.5	18
369	Cutaneous Sensory Disorder. <i>Seminars in Cutaneous Medicine and Surgery</i> , 2013, 32, 110-118.	1.6	18
370	New and emerging concepts in managing and preventing community-associated methicillin-resistant <i>Staphylococcus aureus</i> infections. <i>International Journal of Dermatology</i> , 2015, 54, 1226-1232.	0.5	17
371	Ergonomics in hair restoration surgeons. <i>Journal of Cosmetic Dermatology</i> , 2016, 15, 66-71.	0.8	17
372	Finasteride for hair loss: a review. <i>Journal of Dermatological Treatment</i> , 2022, 33, 1938-1946.	1.1	17
373	A survey of office visits for actinic keratosis as reported by NAMCS, 1990-1999. <i>National Ambulatory Medical Care Survey. Cutis</i> , 2002, 70, 8-13.	0.4	17
374	BETAMETHASONE DIPROPIONATE POLYACRYLIC FILM-FORMING LOTION IN THE TREATMENT OF HAND DERMATITIS. <i>International Journal of Dermatology</i> , 1993, 32, 828-829.	0.5	16
375	THE USE OF PSYCHOTROPIC DRUGS IN DERMATOLOGY. <i>Dermatologic Clinics</i> , 2000, 18, 711-725.	1.0	16
376	Prednicarbate (Dermatop [®]): Profile of a Corticosteroid. <i>Journal of Cutaneous Medicine and Surgery</i> , 2004, 8, 244-249.	0.6	16
377	Biologic Therapeutics in the Treatment of Psoriasis. Part 1: Review. <i>Journal of Cutaneous Medicine and Surgery</i> , 2007, 11, 99-122.	0.6	16
378	How effective is efinaconazole in the management of onychomycosis?. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 611-618.	0.9	16

#	ARTICLE	IF	CITATIONS
379	Emerging drugs for the treatment of onychomycosis. <i>Expert Opinion on Emerging Drugs</i> , 2019, 24, 213-220.	1.0	16
380	Platelet-rich plasma for androgenetic alopecia: Efficacy differences between men and women. <i>Dermatologic Therapy</i> , 2020, 33, e14143.	0.8	16
381	The increasing problem of treatment-resistant fungal infections: a call for antifungal stewardship programs. <i>International Journal of Dermatology</i> , 2021, 60, e474-e479.	0.5	16
382	Chronic idiopathic urticaria associated with panic disorder: a syndrome responsive to selective serotonin reuptake inhibitor antidepressants?. <i>Cutis</i> , 1995, 56, 53-4.	0.4	16
383	Ciclopirox shampoo for treating seborrheic dermatitis. <i>Skin Therapy Letter</i> , 2004, 9, 4-5.	0.3	16
384	Fluconazole for the treatment of onychomycosis: an update. <i>International Journal of Dermatology</i> , 1998, 37, 815-820.	0.5	15
385	PHARMACOLOGY AND THERAPEUTICS: Onychomycosis in Children: Prevalence and Management. <i>Pediatric Dermatology</i> , 1998, 15, 464-471.	0.5	15
386	Toenail Onychomycosis—A Canadian Approach With a New Transungual Treatment. <i>Journal of Cutaneous Medicine and Surgery</i> , 2015, 19, 440-449.	0.6	15
387	When is onychomycosis onychomycosis? A cross-sectional study of fungi in normal-appearing nails. <i>British Journal of Dermatology</i> , 2015, 172, 380-383.	1.4	15
388	How do we measure efficacy of therapy in onychomycosis: Patient, physician, and regulatory perspectives. <i>Journal of Dermatological Treatment</i> , 2016, 27, 498-504.	1.1	15
389	Meta-analysis of photobiomodulation for the treatment of androgenetic alopecia. <i>Journal of Dermatological Treatment</i> , 2021, 32, 643-647.	1.1	15
390	A network meta-analysis on the efficacy and safety of monotherapies for tinea capitis, and an assessment of evidence quality. <i>Pediatric Dermatology</i> , 2020, 37, 1014-1022.	0.5	15
391	Cannabinoids for skin diseases and hair regrowth. <i>Journal of Cosmetic Dermatology</i> , 2021, 20, 2703-2711.	0.8	15
392	Starvation-associated pruritus: A clinical feature of eating disorders. <i>Journal of the American Academy of Dermatology</i> , 1992, 27, 118-120.	0.6	14
393	Safety review of the oral antifungal agents used to treat superficial mycoses. <i>International Journal of Dermatology</i> , 1999, 38, 40-52.	0.5	14
394	The use of the new oral antifungal agents, itraconazole, terbinafine, and fluconazole to treat onychomycosis and other dermatomycoses. <i>Current Problems in Dermatology</i> , 2001, 13, 213-246.	0.1	14
395	Comparison of efficacy criteria across onychomycosis trials: need for standardization. <i>International Journal of Dermatology</i> , 2003, 42, 312-315.	0.5	14
396	Seborrheic dermatitis: current treatment practices. <i>Expert Opinion on Pharmacotherapy</i> , 2004, 5, 1755-1765.	0.9	14

#	ARTICLE	IF	CITATIONS
397	Lasers for Onychomycosis. <i>Journal of Cutaneous Medicine and Surgery</i> , 2017, 21, 114-116.	0.6	14
398	Examining the Benefits of the Boron-Based Mechanism of Action and Physicochemical Properties of Tavaborole in the Treatment of Onychomycosis. <i>Journal of the American Podiatric Medical Association</i> , 2018, 108, 12-19.	0.2	14
399	Use of antiepileptic mood stabilizers in dermatology. <i>Clinics in Dermatology</i> , 2018, 36, 756-764.	0.8	14
400	The Role of Shoe and Sock Sanitization in the Management of Superficial Fungal Infections of the Feet. <i>Journal of the American Podiatric Medical Association</i> , 2019, 109, 141-149.	0.2	14
401	Innovations hair restoration surgeons have made to adapt to the challenges of follicular unit excision. <i>Journal of Cosmetic Dermatology</i> , 2020, 19, 1883-1891.	0.8	14
402	Efficacy and safety of topical terbinafine 10% solution (MOB-015) in the treatment of mild to moderate distal subungual onychomycosis: A randomized, multicenter, double-blind, vehicle-controlled phase 3 study. <i>Journal of the American Academy of Dermatology</i> , 2021, 85, 95-104.	0.6	14
403	Increased incidence of <i>Trichophyton tonsurans</i> tinea capitis in Ontario, Canada between 1985 and 1996. <i>Medical Mycology</i> , 1998, 36, 55-60.	0.3	14
404	Onychomycosis in Older Adults: Prevalence, Diagnosis, and Management. <i>Drugs and Aging</i> , 2022, 39, 191-198.	1.3	14
405	Seborrheic dermatitis of the scalp: etiology and treatment. <i>Journal of Drugs in Dermatology</i> , 2004, 3, 155-8.	0.4	14
406	The Presence of an Air Gap Between the Nail Plate and Nail Bed in Onychomycosis Patients: Treatment Implications for Topical Therapy. <i>Journal of Drugs in Dermatology</i> , 2015, 14, 859-63.	0.4	14
407	<i>Arachnomyces kanei</i> (anamorph<i>Onychocola kanei</i>) sp. nov., from human nails. <i>Medical Mycology</i> , 2002, 40, 573-580.	0.3	13
408	Critical review of the manner in which the efficacy of therapies for rosacea are evaluated. <i>International Journal of Dermatology</i> , 2003, 42, 909-916.	0.5	13
409	Onychomycosis Therapies: Strategies to Improve Efficacy. <i>Dermatologic Clinics</i> , 2006, 24, 381-386.	1.0	13
410	Fungal Skin Infections. <i>Pediatrics in Review</i> , 2017, 38, 8-22.	0.2	13
411	Evaluation of the efficacy and safety of tavaborole topical solution, 5%, in the treatment of onychomycosis of the toenail in adults: a pooled analysis of an 8-week, post-study follow-up from two randomized phase 3 studies. <i>Journal of Dermatological Treatment</i> , 2018, 29, 44-48.	1.1	13
412	The efficacy and safety of pulse vs. continuous therapy for dermatophyte toenail onychomycosis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 580-588.	1.3	13
413	Onychomycosis in children – review on treatment and management strategies. <i>Journal of Dermatological Treatment</i> , 2022, 33, 1213-1224.	1.1	13
414	Itraconazole pulse therapy for tinea capitis: a novel treatment schedule.. <i>Pediatric Dermatology</i> , 1998, 15, 225-228.	0.5	13

#	ARTICLE	IF	CITATIONS
415	Natural products for male androgenetic alopecia. <i>Dermatologic Therapy</i> , 2022, 35, e15323.	0.8	13
416	Ciclopirox nail lacquer: a brush with onychomycosis. <i>Cutis</i> , 2001, 68, 13-6.	0.4	13
417	Zyclara (imiquimod) cream, 3.75%. <i>Skinmed</i> , 2010, 8, 227-9.	0.0	13
418	Sequential pulse therapy with itraconazole and terbinafine to treat onychomycosis of the fingernails. <i>Journal of Dermatological Treatment</i> , 2000, 11, 151-154.	1.1	12
419	Interdigital tinea pedis (dermatophytosis simplex and complex) and treatment with ciclopirox 0.77% gel. <i>International Journal of Dermatology</i> , 2003, 42, 23-27.	0.5	12
420	Prescribing practices for seborrheic dermatitis vary with the physician's specialty: implications for clinical practice. <i>Journal of Dermatological Treatment</i> , 2004, 15, 208-213.	1.1	12
421	Obstructive sleep apnea and dermatologic disorders. <i>Clinics in Dermatology</i> , 2017, 35, 319-327.	0.8	12
422	Changing trends in surgical hair restoration: Use of Google Trends and the ISHRS practice census survey. <i>Journal of Cosmetic Dermatology</i> , 2020, 19, 2974-2981.	0.8	12
423	Tinea capitis: An update. <i>Pediatric Dermatology</i> , 2022, 39, 167-172.	0.5	12
424	Photodamaged skin and quality of life: Reasons for therapy. <i>Journal of Dermatological Treatment</i> , 1996, 7, 261-264.	1.1	11
425	The use of intermittent itraconazole therapy for superficial mycotic infections: a review and update on the 'one week' approach. <i>International Journal of Dermatology</i> , 1999, 38, 28-39.	0.5	11
426	Alefacept: an expert review concerning the treatment of psoriasis. <i>Expert Opinion on Pharmacotherapy</i> , 2005, 6, 2327-2333.	0.9	11
427	Efalizumab in the Treatment of Psoriasis. <i>Journal of Cutaneous Medicine and Surgery</i> , 2006, 10, 57-68.	0.6	11
428	Platelet-rich Plasma and Cell Therapy. <i>Dermatologic Clinics</i> , 2021, 39, 429-445.	1.0	11
429	Follicular Unit Excision Punches and Devices. <i>Dermatologic Surgery</i> , 2020, 46, 1705-1711.	0.4	11
430	Itraconazole oral solution for the treatment of tinea capitis using the pulse regimen. <i>Cutis</i> , 1999, 64, 192-4.	0.4	11
431	Onychomycosis in children: an overview. <i>Journal of Drugs in Dermatology</i> , 2003, 2, 31-4.	0.4	11
432	Diagnosing Onychomycosis: What's New?. <i>Journal of Fungi (Basel, Switzerland)</i> , 2022, 8, 464.	1.5	11

#	ARTICLE	IF	CITATIONS
433	Systemic antifungal agents. , 2013, , 98-120.e3.		11
434	Calcipotriol in the Treatment of Psoriasis of Limited Severity: Pharmacoeconomic Evaluation. Journal of Cutaneous Medicine and Surgery, 1997, 2, 7-15.	0.6	10
435	A questionnaire study on the management of onychomycosis: a Canadian perspective. International Journal of Dermatology, 1998, 37, 457-460.	0.5	10
436	Onychomycosis: Quality of Studies. Journal of Cutaneous Medicine and Surgery, 2003, 7, 312-316.	0.6	10
437	Pathogenesis of Psoriasis and Current Challenges. Journal of Cutaneous Medicine and Surgery, 2004, 8, 3-7.	0.6	10
438	Meta-analysis of 308-nm excimer laser therapy for alopecia areata. Journal of Dermatological Treatment, 2021, 32, 526-529.	1.1	10
439	How good is artificial intelligence (AI) at solving hairy problems? A review of AI applications in hair restoration and hair disorders. Dermatologic Therapy, 2021, 34, e14811.	0.8	10
440	Increased incidence of Trichophyton tonsurans tinea capitis in Ontario, Canada between 1985 and 1996. Medical Mycology, 1998, 36, 55-60.	0.3	10
441	Types of onychomycosis. Cutis, 2001, 68, 4-7.	0.4	10
442	Cyclosporine A. Clinics in Dermatology, 1989, 7, 98-110.	0.8	9
443	Multinational pharmacoeconomic analysis of topical and oral therapies for onychomycosis. Journal of Dermatological Treatment, 1997, 8, 229-235.	1.1	9
444	Oral antifungal drug interactions. Dermatologic Clinics, 2003, 21, 543-563.	1.0	9
445	Progression of Surgical Hair Restoration Techniques. Journal of Cutaneous Medicine and Surgery, 2015, 19, 17-21.	0.6	9
446	Tinea capitis. Medical Mycology, 2000, 38, 255-287.	0.3	9
447	Onychomycosis. Going for cure. Canadian Family Physician, 1997, 43, 299-305.	0.1	9
448	The use of high-frequency ultrasound as a method of assessing the severity of a plaque of psoriasis. Archives of Dermatology, 1996, 132, 658-62.	1.7	9
449	A review of prednicarbate (Dermatop). Skin Therapy Letter, 2004, 9, 5-6, 9.	0.3	9
450	Review of the alternative therapies for onychomycosis and superficial fungal infections: posaconazole, fosravuconazole, voriconazole, oteseconazole. International Journal of Dermatology, 2022, 61, 1431-1441.	0.5	9

#	ARTICLE	IF	CITATIONS
451	EPIDERMOLYSIS BULLOSA ACQUISITA WITH FEATURES OF BULLOUS LUPUS ERYTHEMATOSUS. International Journal of Dermatology, 1994, 33, 192-195.	0.5	8
452	Open-Label Study to Evaluate the Healing Rate and Safety of the Proforea,® Extra Four-Layer Bandage System in Patients with Venous Leg Ulceration. Journal of Cutaneous Medicine and Surgery, 2000, 4, 8-11.	0.6	8
453	Ciclopirox nail lacquer and podiatric practice. Journal of the American Podiatric Medical Association, 2000, 90, 502-507.	0.2	8
454	Multitherapy Approach to Onychomycosis Therapy. Journal of Cutaneous Medicine and Surgery, 2006, 10, S44-S47.	0.6	8
455	Itraconazole Pulse Therapy for Tinea Capitis: A Novel Treatment Schedule. Pediatric Dermatology, 1998, 15, 225-228.	0.5	8
456	Efinaconazole (Jublia) for the treatment of onychomycosis. Expert Review of Anti-Infective Therapy, 2014, 12, 743-752.	2.0	8
457	In vitro efficacy of tavaborole topical solution, 5% after penetration through nail polish on ex vivo human fingernails. Journal of Dermatological Treatment, 2018, 29, 633-636.	1.1	8
458	Efinaconazole 10% topical solution for the treatment of onychomycosis in pediatric patients: Open-label phase 4 study. Journal of the American Academy of Dermatology, 2021, 84, 1140-1142.	0.6	8
459	Topical Treatment of Onychomycosis and Clinically Meaningful Outcomes. Journal of Drugs in Dermatology, 2016, 15, 1260-1266.	0.4	8
460	Prednicarbate (Dermatop®): Profile of a Corticosteroid. Journal of Cutaneous Medicine and Surgery, 2004, 8, 244-247.	0.6	7
461	Assessing dutasteride-associated sexual dysfunction using the U.S. Food and Drug Administration Adverse Event Reporting System. Journal of the European Academy of Dermatology and Venereology, 2018, 32, 1373-1376.	1.3	7
462	Psoriasis Is Associated With a Higher Prevalence of Obstructive Sleep Apnea and Restless Legs Syndrome: A Possible Indication of Autonomic Activation in Psoriasis. Journal of Clinical Sleep Medicine, 2018, 14, 1085-1085.	1.4	7
463	A practical application of onychomycosis cure “ combining patient, physician and regulatory body perspectives. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 281-287.	1.3	7
464	Efficacy of Off-Label Topical Treatments for the Management of Androgenetic Alopecia: A Review. Clinical Drug Investigation, 2019, 39, 233-239.	1.1	7
465	The shifting preferences of patients and physicians in nonsurgical hair loss treatment. Journal of Cosmetic Dermatology, 2021, 20, 929-936.	0.8	7
466	The new oral antifungal agents for onychomycosis of the toenails. , 1999, 13, 1.		7
467	Safety, Pharmacokinetics, and Efficacy of Efinaconazole 10% Topical Solution for Onychomycosis Treatment in Pediatric Patients. Journal of Drugs in Dermatology, 2020, 19, 867-872.	0.4	7
468	Topical cyclosporine A inhibits the phorbol ester induced hyperplastic inflammatory response but not protein kinase C activation in mouse epidermis. Journal of Investigative Dermatology, 1989, 93, 379-86.	0.3	7

#	ARTICLE	IF	CITATIONS
469	Terbinafine for the treatment of pedal onychomycosis. A foot closer to the promised land of cured nails?. Archives of Dermatology, 1995, 131, 937-42.	1.7	7
470	Analysis of factors associated with increased prescription illegibility: results from the National Ambulatory Medical Care Survey, 1990-1998. American Journal of Managed Care, 2003, 9, 548-52.	0.8	7
471	Trichotillomania: Demographic and Clinical Features From a Nationally Representative US Sample. Skinmed, 2015, 13, 455-60.	0.0	7
472	Onychomycosis: Does Cure Equate to Treatment Success?. Journal of Drugs in Dermatology, 2016, 15, 626-32.	0.4	7
473	Topical finasteride for male and female pattern hair loss: Is it a safe and effective alternative?. Journal of Cosmetic Dermatology, 2022, 21, 1841-1848.	0.8	7
474	Utility of polymerase chain reaction for assessment of onychomycosis during topical therapy. International Journal of Dermatology, 2022, 61, 1385-1389.	0.5	7
475	The use of low-energy photon therapy in the treatment of leg ulcers – a preliminary study. Journal of Dermatological Treatment, 1997, 8, 103-108.	1.1	6
476	Evaluation of the in vitro and in vivo efficacy of butenafine hydrochloride cream 1% against Malassezia furfur species and seborrheic dermatitis. Journal of Dermatological Treatment, 2000, 11, 79-83.	1.1	6
477	Pharmacoeconomic Assessment of Ciclopirox Topical Solution, 8%, Oral Terbinafine, and Oral Itraconazole for Onychomycosis. Journal of Cutaneous Medicine and Surgery, 2006, 10, S54-S62.	0.6	6
478	A Double-Blind, Randomized, Placebo-Controlled Trial of Eutectic Lidocaine/Prilocaine Cream 5% (EMLA)® for Analgesia Prior to Cryotherapy of Warts in Children and Adults. Pediatric Dermatology, 2009, 15, 129-133.	0.5	6
479	Efinaconazole 10% Nail Solution. Journal of Cutaneous Medicine and Surgery, 2014, 18, 151-155.	0.6	6
480	Griseofulvin and Fluconazole Reduce Transmission of Tinea Capitis in Schoolchildren. Pediatric Dermatology, 2015, 32, 696-700.	0.5	6
481	Once Weekly Application of Urea 40% and Bifonazole 1% Leads to Earlier Nail Removal in Onychomycosis. Skin Appendage Disorders, 2020, 6, 304-308.	0.5	6
482	Analysis of YouTube hair loss treatment information: What makes for engaging content?. Dermatologic Therapy, 2020, 33, e14244.	0.8	6
483	Clearance of head and neck involvement in plaque psoriasis with tildrakizumab treatment in the phase 3 reSURFACE 1 study. Journal of the European Academy of Dermatology and Venereology, 2020, 34, e803-e805.	1.3	6
484	Reduced risk of suicidal behaviours associated with the treatment of hidradenitis suppurativa with tumour necrosis factor alpha antagonists: results from the <sc>US FDA</sc> Adverse Events Reporting System pharmacovigilance database. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 1564-1568.	1.3	6
485	Hair loss treatment information on Facebook: Content analysis and comparison with other online sources. Journal of Cosmetic Dermatology, 2021, 20, 577-583.	0.8	6
486	Continuous terbinafine and pulse itraconazole for the treatment of non-dermatophyte mold toenail onychomycosis. Journal of Dermatological Treatment, 2021, 32, 310-313.	1.1	6

#	ARTICLE	IF	CITATIONS
487	One size does not fit all: the need for individualized treatment based on factors that may affect the therapeutic outcome of efinaconazole 10% solution for the treatment of toenail onychomycosis. <i>International Journal of Dermatology</i> , 2021, 60, 1296-1302.	0.5	6
488	Short-term changes in renal function, blood pressure, and electrolyte levels in patients receiving cyclosporine for dermatologic disorders. <i>Archives of Internal Medicine</i> , 1991, 151, 356-362.	4.3	6
489	Itraconazole in the treatment of superficial cutaneous and mucosal <i>Candida</i> infections. <i>Journal of the American Osteopathic Association</i> , The, 1998, 98, 497-502.	1.7	6
490	The new oral antifungal agents for onychomycosis of the toenails. <i>Journal of the European Academy of Dermatology and Venereology</i> , 1999, 13, 1-13.	1.3	6
491	Sinecatechins 10% ointment: a green tea extract for the treatment of external genital warts. <i>Skin Therapy Letter</i> , 2015, 20, 6-8.	0.3	6
492	There Is a Positive Dose-Dependent Association between Low-Dose Oral Minoxidil and Its Efficacy for Androgenetic Alopecia: Findings from a Systematic Review with Meta-Regression Analyses. <i>Skin Appendage Disorders</i> , 2022, 8, 355-361.	0.5	6
493	Effect of steroid ingestion on pancreatic echogenicity. <i>Journal of Clinical Ultrasound</i> , 1987, 15, 171-174.	0.4	5
494	Application of a eutectic mixture of lidocaine/prilocaine cream to the moustache area prior to electrolysis provides effective analgesia. <i>Journal of Dermatological Treatment</i> , 1995, 6, 89-94.	1.1	5
495	Dermatological complications. , 2000, 8, 134-143.		5
496	Uncommon localization or presentation of tinea infection. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2001, 15, 7-8.	1.3	5
497	Management of toe onychomycosis: what is the potential for improving efficacy of treatment? Edited by Stephen P. Stone. <i>Clinics in Dermatology</i> , 2002, 20, 607-609.	0.8	5
498	Nonpsoriatic Uses of Calcipotriol. <i>Journal of Cutaneous Medicine and Surgery</i> , 2002, 6, 442-448.	0.6	5
499	Ciclopirox gel: an update. <i>International Journal of Dermatology</i> , 2003, 42, 1-2.	0.5	5
500	The Relationship Between Dermatologist- and Patient-Reported Acne Severity Measures and Treatment Recommendations. <i>Journal of Cutaneous Medicine and Surgery</i> , 2015, 19, 464-469.	0.6	5
501	Clinical trials of lasers for toenail onychomycosis: The implications of new regulatory guidance. <i>Journal of Dermatological Treatment</i> , 2017, 28, 264-270.	1.1	5
502	Factors influencing the effect of photobiomodulation in the treatment of androgenetic alopecia: A systematic review and analyses of summary-level data. <i>Dermatologic Therapy</i> , 2020, 33, e14191.	0.8	5
503	Labeled use of efinaconazole topical solution 10% in treating onychomycosis in children and a review of the management of pediatric onychomycosis. <i>Dermatologic Therapy</i> , 2020, 33, e13613.	0.8	5
504	Preview long hair follicular unit excision: An upâ€coming technique. <i>Journal of Cosmetic Dermatology</i> , 2021, 20, 3422-3426.	0.8	5

#	ARTICLE	IF	CITATIONS
505	Management of tinea capitis in Israel: A comparative study. <i>Pediatric Dermatology</i> , 2021, 38, 806-811.	0.5	5
506	Efinaconazole in Onychomycosis. <i>American Journal of Clinical Dermatology</i> , 2022, 23, 207-218.	3.3	5
507	Short-term changes in renal function, blood pressure, and electrolyte levels in patients receiving cyclosporine for dermatologic disorders. <i>Archives of Internal Medicine</i> , 1991, 151, 356-62.	4.3	5
508	Advances in Hair Transplantation Technology: Multiphasic Device for Follicular Unit Excision. <i>Skinmed</i> , 2019, 17, 241-246.	0.0	5
509	Peripheral Edema Due to Nifedipine-Itraconazole Interaction: A Case Report. <i>Archives of Dermatology</i> , 1996, 132, 350.	1.7	4
510	Brief Treatment Guide for Onychomycosis. <i>Journal of Cutaneous Medicine and Surgery</i> , 2006, 10, S39-S43.	0.6	4
511	Comparison of visual assessments versus planimetry assessments in a large-scale clinical trial of onychomycosis. <i>Journal of Dermatological Treatment</i> , 2014, 25, 256-259.	1.1	4
512	Bidirectional Relationship between Obstructive Sleep Apnea (OSA) and Psoriasis: Implications for OSA Therapies?. <i>Journal of Clinical Sleep Medicine</i> , 2016, 12, 1309-1309.	1.4	4
513	A Retrospective Study Comparing K101 Nail Solution as a Monotherapy and in Combination with Oral Terbinafine or Itraconazole for the Treatment of Toenail Onychomycosis. <i>Skin Appendage Disorders</i> , 2018, 4, 166-170.	0.5	4
514	The color of skin: psychiatric ramifications. <i>Clinics in Dermatology</i> , 2019, 37, 437-446.	0.8	4
515	The edge out punch: An advancement that reduces transections in follicular unit excision hair transplantation. <i>Journal of Cosmetic Dermatology</i> , 2020, 19, 2194-2200.	0.8	4
516	Efficacy of non-surgical monotherapies for hidradenitis suppurativa: a systematic review and network meta-analyses of randomized trials. <i>Journal of Dermatological Treatment</i> , 2021, , 1-32.	1.1	4
517	Low-dose isotretinoin versus minocycline in the treatment of rosacea. <i>Dermatologic Therapy</i> , 2021, 34, e14986.	0.8	4
518	Increased incidence of <i>Trichophyton tonsurans</i> tinea capitis in Ontario, Canada between 1985 and 1996. <i>Medical Mycology</i> , 1998, 36, 55-60.	0.3	4
519	Onychomycosis: review of recurrence rates, poor prognostic factors, and strategies to prevent disease recurrence. <i>Cutis</i> , 2004, 74, 10-5.	0.4	4
520	Tavaborole 5% Solution: A Novel Topical Treatment for Toenail Onychomycosis. <i>Skin Therapy Letter</i> , 2015, 20, 6-9.	0.3	4
521	Evaluating the Quality of Rosacea Studies: Implications for the Patient and Physician. <i>Dermatology</i> , 2003, 207, 173-177.	0.9	3
522	Pathogenesis of Psoriasis and Current Challenges. <i>Journal of Cutaneous Medicine and Surgery</i> , 2004, 8, 3-7.	0.6	3

#	ARTICLE	IF	CITATIONS
523	Fungus-free versus disease-free nails: Reply. <i>Journal of the American Academy of Dermatology</i> , 2004, 50, 152-153.	0.6	3
524	Oracea (doxycycline monohydrate). <i>Skinmed</i> , 2006, 5, 238-240.	0.0	3
525	Position Statement for Isotretinoin. <i>Journal of Cutaneous Medicine and Surgery</i> , 2007, 11, 123-124.	0.6	3
526	Nails and the clinician. <i>Clinics in Dermatology</i> , 2013, 31, 507-508.	0.8	3
527	Placebo Cure Rates in the Treatment of Onychomycosis. <i>Journal of the American Podiatric Medical Association</i> , 2014, 104, 277-282.	0.2	3
528	Onychomycosis: Clinical Aspects. , 2018, , 153-159.		3
529	A Step Toward Standardizing Clinical Trials of Actinic Keratosis. <i>JAMA Dermatology</i> , 2020, 156, 255.	2.0	3
530	More than Nail Deep: The Effect of Efinaconazole 10% Treatment on the Quality of Life in Patients with Onychomycosis: A post hoc Study. <i>Skin Appendage Disorders</i> , 2021, 7, 272-279.	0.5	3
531	Hair transplantation Follicular Unit Excision (FUE): Introducing the multipurpose octagonal ring punch. <i>Journal of Cosmetic Dermatology</i> , 2021, 20, 2602-2605.	0.8	3
532	Efficacy of lasers for the management of dermatophyte toenail onychomycosis. <i>Journal of the American Podiatric Medical Association</i> , 2021, , .	0.2	3
533	Papular midfacial eruption in a child. <i>Cutaneous Sarcoidosis. Archives of Dermatology</i> , 1989, 125, 1704-1705.	1.7	3
534	Dermatophytosis (Tinea) and Other Superficial Fungal Infections. , 2008, , 355-381.		3
535	Superficial and subcutaneous fungal pathogens. , 2010, , 1853-1867.		3
536	<i>Trichophyton rubrum</i> DNA Strains in Patients with Onychomycosis with Persistent Mixed Infections Involving a Nondermatophyte Mold. <i>Journal of the American Podiatric Medical Association</i> , 2020, 110, .	0.2	3
537	Onychomycosis. New therapies for an old disease. <i>Western Journal of Medicine</i> , 1996, 165, 349-51.	0.3	3
538	The effect of placebo in split-scalp and whole-head platelet-rich plasma trials for androgenetic alopecia differs: Findings from a systematic review with quantitative evidence syntheses. <i>Journal of Cosmetic Dermatology</i> , 2022, 21, 1454-1463.	0.8	3
539	5-fluorouracil 0.5% cream for multiple actinic or solar keratoses of the face and anterior scalp. <i>Skin Therapy Letter</i> , 2001, 6, 1-4.	0.3	3
540	Prednicarbate (dermatop): a review. <i>Journal of Drugs in Dermatology</i> , 2004, 3, 553-6.	0.4	3

#	ARTICLE	IF	CITATIONS
541	Adalimumab (Humira) for the Treatment of Hidradenitis Suppurativa. <i>Skin Therapy Letter</i> , 2016, 21, 1-4.	0.3	3
542	Bavencio (Avelumab)-A Newly Approved Anti-PD-L1 IgG1 Antibody. <i>Skinmed</i> , 2018, 16, 183-187.	0.0	3
543	Exosomes: A New Effective Non-Surgical Therapy for Androgenetic Alopecia?. <i>Skinmed</i> , 2020, 18, 96-100.	0.0	3
544	Diagnosing onychomycosis: A step forward?. <i>Journal of Cosmetic Dermatology</i> , 2022, 21, 530-535.	0.8	3
545	Potential use of microwave technology in dermatology. <i>Journal of Dermatological Treatment</i> , 2022, 33, 2899-2910.	1.1	3
546	Verapamil prevents insulin antinatriuresis in euglycemic rats. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 1992, 262, R1145-R1148.	0.9	2
547	Pityriasis versicolor: quality of studies. <i>Journal of Dermatological Treatment</i> , 2004, 15, 40-45.	1.1	2
548	Canadian Perspectives on Antifungal Treatment for Onychomycosis. <i>Journal of Cutaneous Medicine and Surgery</i> , 2006, 10, S34-S38.	0.6	2
549	New Therapy Update. <i>Skinmed</i> , 2006, 5, 136-138.	0.0	2
550	Solodyn (Minocycline HCl, USP) Extended-Release Tablets. <i>Skinmed</i> , 2006, 5, 291-292.	0.0	2
551	Altabax (retapamulin ointment), 1%. <i>Skinmed</i> , 2007, 6, 239-240.	0.0	2
552	Xyzal (levocetirizine dihydrochloride). <i>Skinmed</i> , 2008, 7, 84-85.	0.0	2
553	Topical and device-based treatments for fungal infections of the toenails. <i>The Cochrane Library</i> , 2016, , .	1.5	2
554	Systemic Antifungal Agents. , 2021, , 99-113.e4.		2
555	Efinaconazole topical solution (10%) for the treatment of onychomycosis in adult and pediatric patients. <i>Expert Review of Anti-Infective Therapy</i> , 2021, , 1-13.	2.0	2
556	Evaluating the Role of Stress in Skin Disease. , 2017, , 11-17.		2
557	Tinea manus treated with 1-week itraconazole vs. terbinafine. <i>International Journal of Dermatology</i> , 2000, 39, 529-531.	0.5	2
558	Are boosters or supplementation of antifungal drugs of any use for treating onychomycosis?. <i>Journal of Drugs in Dermatology</i> , 2002, 1, 35-41.	0.4	2

#	ARTICLE	IF	CITATIONS
559	Management of onychomycosis: examining the role of monotherapy and dual, triple, or quadruple therapies. <i>Cutis</i> , 2004, 74, 5-9.	0.4	2
560	Ciclopirox (Loprox) gel for superficial fungal infections. <i>Skin Therapy Letter</i> , 2004, 9, 4-5, 9.	0.3	2
561	Update on Efinaconazole 10% Topical Solution for the Treatment of Onychomycosis. <i>Skin Therapy Letter</i> , 2016, 21, 7-11.	0.3	2
562	Odomzo (Sonidegib). <i>Skinmed</i> , 2018, 16, 35-38.	0.0	2
563	Ilumya® (Tildrakizumab): A Newly Approved Interleukin-23 Antagonist for the Treatment of Plaque Psoriasis. <i>Skinmed</i> , 2018, 16, 321-324.	0.0	2
564	Hair loss treatment and restoration: Online interest trends and video-based social media content. <i>Journal of Cosmetic Dermatology</i> , 2022, 21, 5902-5909.	0.8	2
565	Cigarette smoking and short-term treatment responsiveness of moderate to severe psoriasis. <i>Journal of Dermatological Treatment</i> , 1998, 9, 7-9.	1.1	1
566	COMMON FUNGAL INFECTIONS. , 2001, , 42-56.		1
567	Ziana (Clindamycin Phosphate 1.2% and Tretinoin 0.025%)Gel. <i>Skinmed</i> , 2007, 6, 85-87.	0.0	1
568	Biologic Therapeutics in the Treatment of Psoriasis. Part 2: Practical Considerations. <i>Journal of Cutaneous Medicine and Surgery</i> , 2007, 11, 145-149.	0.6	1
569	Terbinafine Pulse Therapy Is Effective in Tinea Capitis. <i>Pediatric Dermatology</i> , 1998, 15, 56-58.	0.5	1
570	Skin Picking and the Role of Stress. , 2017, , 87-97.		1
571	0917 Finasteride is Associated with a Higher Odds of Obstructive Sleep Apnea (OSA): Results from the US FDA Adverse Events Reporting System (FAERS). <i>Sleep</i> , 2018, 41, A340-A341.	0.6	1
572	An elevated leg movement index during sleep in atopic dermatitis and periodic leg movement disorder may be an indication of sympathetic activation common to both. <i>Journal of Clinical Sleep Medicine</i> , 2020, 16, 463-463.	1.4	1
573	Topical Antifungal Agents. , 2021, , 480-492.e5.		1
574	Onychomycosis in the Twenty-First Century: An Update on Epidemiology and Diagnosis. , 2021, , 41-64.		1
575	Artificial hair implantation for hair restoration. <i>Journal of Dermatological Treatment</i> , 2021, , 1-7.	1.1	1
576	Fungal Lung: The Risk of Fungal Exposure to Nail Care Professionals. <i>Journal of the American Podiatric Medical Association</i> , 2021, , .	0.2	1

#	ARTICLE	IF	CITATIONS
577	Results of the First COVID Impact Member Survey. International Society of Hair Restoration Surgery, 2020, 30, 91.2-91.	0.1	1
578	Sleep/wake detection by behavioral response to haptic stimuli may be confounded by the sleep stage during which the haptic stimuli are delivered. Journal of Clinical Sleep Medicine, 2020, 16, 823-823.	1.4	1
579	Itraconazole (Sporanox®) for vulvovaginal candidiasis. Skin Therapy Letter, 2002, 7 Suppl 1, 1-3.	0.3	1
580	ONMEL (itraconazole) 200-mg tablet. Skinmed, 2013, 11, 105-7.	0.0	1
581	Efinaconazole: a new topical treatment for onychomycosis. Skin Therapy Letter, 2014, 19, 1-4.	0.3	1
582	Surgical hair restoration and the advent of a robotic-assisted extraction device. Skinmed, 2014, 12, 213-6.	0.0	1
583	Ozenoxacin Cream, 1% - Topical Treatment of Impetigo. Skinmed, 2017, 15, 57-59.	0.0	1
584	From the Cochrane library: Topical and device-based treatments for fungal infections of the toenails. Journal of the American Academy of Dermatology, 2022, 86, e221-e222.	0.6	1
585	Perioral Dermatitis. , 0, , 111-116.		1
586	Terbinafine: An alternative treatment for tinea faciei. Journal of Dermatological Treatment, 1995, 6, 187-188.	1.1	0
587	Pharmacoeconomics for Dermatologists: An Introduction. Journal of Cutaneous Medicine and Surgery, 1997, 1, 185-189.	0.6	0
588	Ciclopirox 1% shampoo is a safe and effective treatment for seborrheic dermatitis. International Journal of Dermatology, 2004, 43, 1-2.	0.5	0
589	REPLY TO DIEHL. Pediatric Dermatology, 2005, 22, 372-372.	0.5	0
590	Fluorouracil Formulations for the Treatment of Actinic Keratosis. American Journal of Cancer, 2005, 4, 115-126.	0.4	0
591	Nail Disorders and their Management. Dermatologic Clinics, 2006, 24, ix-x.	1.0	0
592	Clobex (clobetasol propionate) Spray, 0.05%. Skinmed, 2006, 5, 184-185.	0.0	0
593	New Therapy Update. Skinmed, 2007, 6, 28-29.	0.0	0
594	Extina Foam (2%). Skinmed, 2007, 6, 186-187.	0.0	0

#	ARTICLE	IF	CITATIONS
595	Differin (adapalene) Gel, 0.3%. Skinmed, 2007, 6, 287-288.	0.0	0
596	Itraconazole Oral Solution for the Treatment of Onychomycosis. Pediatric Dermatology, 2009, 15, 472-474.	0.5	0
597	Topical treatments for athlete's foot. The Cochrane Library, 2013, , .	1.5	0
598	Topical Treatment of Onychomycosis as a Realistic Option to Systemic Therapy. Journal of the American Podiatric Medical Association, 2014, 104, 115-117.	0.2	0
599	Topical treatments and photodynamic therapy for actinic keratosis of the face and scalp. The Cochrane Library, 2019, , .	1.5	0
600	Response to Raschi E et al . 'Reduced reporting of neuropsychiatric adverse events with tumor necrosis factor alpha inhibitors for hidradenitis suppurativa: caution before concluding for risk reduction'. Journal of the European Academy of Dermatology and Venereology, 2020, 34, e431-e432.	1.3	0
601	Google search trends in onychomycosis: Influences of flip flops and advertising. Journal of Cosmetic Dermatology, 2020, 19, 2736-2744.	0.8	0
602	New Antifungal Agents and New Formulations Against Dermatophytes. , 2021, , 433-471.		0
603	Fungal Skin Infections (Mycology). , 2022, , 77-111.		0
604	Fungal Skin Infections (Mycology). , 2019, , 1-35.		0
605	Management of onychomycosis in children. Postgraduate Medicine, 1999, Spec No, 31-7.	0.9	0
606	Ciclopirox nail lacquer topical solution 8%. Skin Therapy Letter, 2000, 6, 1-5.	0.3	0
607	Topical metronidazole for rosacea. Skin Therapy Letter, 2002, 7, 1-3, 6.	0.3	0
608	Itraconazole (Sporanox®) for seborrheic dermatitis. Skin Therapy Letter, 2002, 7 Suppl 1, 4-5, 8.	0.3	0
609	Butenafine: an update of its use in superficial mycoses. Skin Therapy Letter, 2002, 7, 1-2, 5.	0.3	0
610	Lustra, Lustra-AF and Alustra. Skin Therapy Letter, 2003, 8, 1-3.	0.3	0
611	Efinaconazole 10% nail solution. Skinmed, 2013, 11, 239-41.	0.0	0
612	OPDIVO (Nivolumab). Skinmed, 2015, 13, 471-4.	0.0	0

#	ARTICLE	IF	CITATIONS
613	VALCHLOR (Mechlorethamine) 0.02% Gel. Skinmed, 2016, 14, 120-2.	0.0	0
614	JUBLIA (Efinaconazole): An Update. Skinmed, 2016, 14, 207-9.	0.0	0
615	Adalimumab (Humira) for Hidradenitis Suppurativa. Skinmed, 2016, 14, 291-294.	0.0	0
616	FINACEA (Azelaic Acid) Foam, 15. Skinmed, 2016, 14, 445-447.	0.0	0
617	AMELUZ (BF-200 ALA). Skinmed, 2017, 15, 133-135.	0.0	0
618	Brodalumab (Siliq): A Treatment for Plaque Psoriasis. Skinmed, 2017, 15, 281-285.	0.0	0
619	Crisaborole 2% Ointment (Eucrisa). Skinmed, 2017, 15, 377-380.	0.0	0
620	Cimzia®,¢ (Certolizumab Pegol). Skinmed, 2018, 16, 400-402.	0.0	0
621	Dupixent® (Dupilumab): A Newly Approved Interleukin-4 Receptor Antagonist for the Treatment of Atopic Dermatitis in Pediatric Patients. Skinmed, 2019, 17, 107-109.	0.0	0
622	DUOBRII®,¢ (Halobetasol Propionate and Tazarotene) Lotion for Topical Use: A Newly Approved Combination Corticosteroid and Retinoid Topical Treatment of Plaque Psoriasis in Adults. Skinmed, 2019, 17, 181-183.	0.0	0
623	ARAZLO (Tazarotene 0.045%) Lotion for Topical Treatment of Acne Vulgaris. Skinmed, 2020, 18, 102-105.	0.0	0
624	Finasteride Use Is Associated with Higher Odds of Obstructive Sleep Apnea: Results from the US Food and Drug Administration Adverse Events Reporting System. Skinmed, 2020, 18, 146-150.	0.0	0
625	AKLIEF (Trifarotene 0.005% [50 ¼g/g] Cream) for Topical Treatment of Acne Vulgaris. Skinmed, 2020, 18, 160-163.	0.0	0
626	Actinic Keratoses and Bowen's Disease. , 0, , 294-314.		0
627	Onychomycosis. , 0, , 362-385.		0